|
G |
Aaas |
aladin WD repeat nucleoporin |
affects response to substance |
ISO |
AAAS protein affects the susceptibility to Paraquat |
CTD |
PMID:23315990 |
|
NCBI chr 7:143,937,198...143,956,668
Ensembl chr 7:143,937,199...143,956,668
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
ISO |
Paraquat results in increased expression of ABCA1 mRNA Paraquat results in decreased expression of ABCA1 protein TO-901317 inhibits the reaction [Paraquat results in decreased expression of ABCA1 protein] |
CTD |
PMID:27788593 PMID:28480221 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects expression |
ISO EXP |
[Doxorubicin results in increased expression of ABCB1 protein] which results in decreased susceptibility to Paraquat; ABCB1 protein affects the reaction [Doxorubicin results in decreased susceptibility to Paraquat]; ABCB1 protein results in increased export of and results in decreased susceptibility to Paraquat; valspodar inhibits the reaction [ABCB1 protein results in increased export of Paraquat] Paraquat affects the expression of ABCB1A mRNA [ABCB1A gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of HAVCR1 mRNA; [ABCB1A gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of LCN2 mRNA; [ABCB1A gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of NQO1 mRNA; ABCB1A protein results in increased export of and results in decreased susceptibility to Paraquat |
CTD |
PMID:16854511 PMID:23220037 PMID:25015657 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression multiple interactions |
EXP ISO |
Paraquat results in increased expression of ABCB1B mRNA [ABCB1B gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of HAVCR1 mRNA; [ABCB1B gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of LCN2 mRNA; [ABCB1B gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of NQO1 mRNA; ABCB1B protein results in increased export of and results in decreased susceptibility to Paraquat |
CTD |
PMID:11557130 PMID:15177642 PMID:25015657 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases expression |
ISO |
ABCC1 protein promotes the reaction [cycloartenyl ferulate results in increased transport of and results in decreased abundance of Paraquat]; cycloartenyl ferulate inhibits the reaction [Paraquat results in decreased expression of ABCC1 protein] |
CTD |
PMID:26358524 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
affects expression |
EXP |
Paraquat affects the expression of ABCC4 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
affects expression |
EXP |
Paraquat affects the expression of ABCC9 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Paraquat results in increased expression of ABCG2 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abhd17b |
abhydrolase domain containing 17B, depalmitoylase |
increases expression |
ISO |
Paraquat results in increased expression of ABHD17B mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:239,266,140...239,301,133
Ensembl chr 1:239,266,921...239,301,176
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
increases expression |
ISO |
Paraquat results in increased expression of ABL1 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation multiple interactions |
EXP ISO |
Paraquat results in increased phosphorylation of ACACA protein PRKAA1 protein affects the reaction [Paraquat results in increased phosphorylation of ACACA protein] |
CTD |
PMID:27324791 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
affects expression |
EXP |
Paraquat affects the expression of ACADL mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Paraquat results in decreased expression of ACAN mRNA |
CTD |
PMID:26108578 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions decreases expression decreases activity affects expression |
ISO EXP |
pimagedine inhibits the reaction [Paraquat results in decreased activity of ACE protein] Paraquat results in decreased expression of ACE mRNA Paraquat affects the expression of ACE protein Curcumin inhibits the reaction [Paraquat affects the expression of ACE protein]; Unithiol inhibits the reaction [Paraquat results in decreased expression of ACE mRNA] |
CTD |
PMID:10666014 PMID:12161173 PMID:16182431 PMID:20465954 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions decreases expression |
EXP |
Unithiol inhibits the reaction [Paraquat results in decreased expression of ACE2 mRNA] |
CTD |
PMID:20465954 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity increases expression |
ISO EXP |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA Paraquat results in decreased activity of ACHE protein Paraquat results in increased expression of ACHE mRNA |
CTD |
PMID:23017109 PMID:28916328 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Aco1 |
aconitase 1 |
increases activity decreases expression decreases activity |
ISO EXP |
Paraquat results in increased activity of ACO1 protein Paraquat results in decreased expression of ACO1 protein Paraquat results in decreased activity of ACO1 protein |
CTD |
PMID:11520895 PMID:15664434 PMID:17324120 PMID:28542246 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
decreases activity multiple interactions affects response to substance |
ISO EXP |
Paraquat results in decreased activity of ACO2 protein [GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased activity of ACO2 protein; [Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA ACO2 protein affects the susceptibility to Paraquat ACO2 protein affects the reaction [Paraquat results in increased abundance of Hydrogen Peroxide]; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron] SNCA protein inhibits the reaction [Paraquat results in decreased activity of ACO2 protein] |
CTD |
PMID:11520895 PMID:15234109 PMID:18386188 PMID:21517855 PMID:23704229 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
affects expression |
EXP |
Paraquat affects the expression of BACH mRNA |
CTD |
PMID:15206577 |
|
NCBI chr 5:169,357,582...169,450,215
Ensembl chr 5:169,357,517...169,450,219
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
affects expression decreases expression |
EXP |
Paraquat affects the expression of ACSL1 mRNA Paraquat results in decreased expression of ACSL1 mRNA |
CTD |
PMID:15206577 PMID:18198484 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions increases expression |
ISO EXP |
CMA1 protein promotes the reaction [Paraquat results in increased expression of ACTA2 protein]; HIF1A protein affects the reaction [Paraquat results in increased expression of ACTA2 protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]]; Anthocyanins inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Anthocyanins inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]; HIF1A protein affects the reaction [Paraquat results in increased expression of ACTA2 protein]; Rosiglitazone inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Rosiglitazone inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]; TRAM 34 inhibits the reaction [Paraquat results in increased expression of ACTA2 protein] Paraquat results in increased expression of ACTA2 mRNA; Paraquat results in increased expression of ACTA2 protein ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; enterotoxin C, staphylococcal analog inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]; pirfenidone inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]; thymoquinone inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17215068 PMID:19969051 PMID:24893116 PMID:25304964 PMID:25873302 PMID:25945502 PMID:26099602 PMID:26758514 PMID:26781174 PMID:26824344 PMID:27375216 PMID:29273418 PMID:30036685 PMID:30317802 PMID:30403199 PMID:30797787 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
Paraquat results in increased expression of ACTB mRNA |
CTD |
PMID:20883675 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Acvr1 |
activin A receptor type 1 |
affects expression decreases expression |
EXP |
Paraquat affects the expression of ACVR1 mRNA Paraquat results in decreased expression of ACVR1 mRNA |
CTD |
PMID:15206577 PMID:18198484 |
|
NCBI chr 3:44,432,476...44,539,680
Ensembl chr 3:44,432,471...44,522,930
|
|
G |
Acvr2a |
activin A receptor type 2A |
decreases expression affects expression |
EXP |
Paraquat results in decreased expression of ACVR2A mRNA Paraquat affects the expression of ACVR2A mRNA |
CTD |
PMID:16854511 PMID:18198484 |
|
NCBI chr 3:32,947,901...33,034,598
Ensembl chr 3:32,947,378...33,034,282
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases expression |
ISO |
Paraquat results in increased expression of ADAM17 mRNA; Paraquat results in increased expression of ADAM17 protein |
CTD |
PMID:29495171 |
|
NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA Paraquat results in increased expression of ADAM22 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:22,864,485...23,002,969
Ensembl chr 4:22,859,622...22,996,645
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
EXP |
Paraquat results in increased expression of ADCY5 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcy6 |
adenylate cyclase 6 |
increases expression |
EXP |
Paraquat results in increased expression of ADCY6 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
decreases response to substance |
ISO |
ADCYAP1 protein results in decreased susceptibility to Paraquat |
CTD |
PMID:23500093 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:115,766,484...115,828,514
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
affects expression |
EXP |
Paraquat affects the expression of ADGRL1 mRNA |
CTD |
PMID:15493455 |
|
NCBI chr19:25,029,037...25,069,146
Ensembl chr19:25,029,037...25,069,142
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]; ADIPOQ protein promotes the reaction [Paraquat results in increased expression of ADIPOR1 mRNA]; ADIPOQ protein promotes the reaction [Paraquat results in increased expression of ADIPOR1 protein]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]] ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of MMP9 protein]; ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]; ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of TIMP1 protein] |
CTD |
PMID:25945502 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions increases expression |
ISO |
ADIPOQ protein promotes the reaction [Paraquat results in increased expression of ADIPOR1 mRNA]; ADIPOQ protein promotes the reaction [Paraquat results in increased expression of ADIPOR1 protein]; ADIPOR1 protein inhibits the reaction [Paraquat results in increased expression of ADIPOR2 mRNA]; ADIPOR1 protein inhibits the reaction [Paraquat results in increased expression of ADIPOR2 protein]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]] Paraquat results in increased expression of ADIPOR1 mRNA; Paraquat results in increased expression of ADIPOR1 protein |
CTD |
PMID:25945502 |
|
NCBI chr13:51,240,470...51,260,233
Ensembl chr13:51,240,911...51,260,228
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions increases expression |
ISO |
ADIPOR1 protein inhibits the reaction [Paraquat results in increased expression of ADIPOR2 mRNA]; ADIPOR1 protein inhibits the reaction [Paraquat results in increased expression of ADIPOR2 protein] Paraquat results in increased expression of ADIPOR2 mRNA; Paraquat results in increased expression of ADIPOR2 protein |
CTD |
PMID:25945502 |
|
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Adora2a |
adenosine A2a receptor |
affects expression increases expression |
EXP |
Paraquat affects the expression of ADORA2A mRNA Paraquat results in increased expression of ADORA2A mRNA |
CTD |
PMID:16854511 PMID:17077588 PMID:18198484 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
increases expression |
ISO |
Paraquat results in increased expression of ADPRH mRNA |
CTD |
PMID:21371552 |
|
NCBI chr11:64,861,772...64,868,112
Ensembl chr11:64,861,768...64,868,108
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
decreases expression |
EXP |
Paraquat results in decreased expression of ADRA1A mRNA |
CTD |
PMID:17077588 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
decreases expression |
EXP |
Paraquat results in decreased expression of ADRA1D mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases secretion multiple interactions increases expression |
EXP |
Paraquat results in decreased secretion of AGER protein modified form Febuxostat inhibits the reaction [Paraquat results in decreased secretion of AGER protein modified form]; Febuxostat inhibits the reaction [Paraquat results in increased expression of AGER mRNA] |
CTD |
PMID:30726711 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA Paraquat results in increased expression of AGO3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:144,355,792...144,436,509
Ensembl chr 5:144,364,269...144,436,509
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases expression increases secretion |
ISO |
AGT protein modified form promotes the reaction [Paraquat results in increased expression of TGFB1 protein]; CMA1 protein promotes the reaction [Paraquat results in increased expression of AGT protein modified form] Paraquat results in increased expression of AGT mRNA; Paraquat results in increased expression of AGT protein modified form Paraquat results in increased secretion of AGT protein |
CTD |
PMID:19969051 PMID:20035857 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Paraquat results in increased expression of AGTR1 mRNA; Paraquat results in increased expression of AGTR1 protein |
CTD |
PMID:20035857 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of AGTR2 mRNA |
CTD |
PMID:20035857 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Ahnak |
AHNAK nucleoprotein |
increases expression |
ISO |
Paraquat results in increased expression of AHNAK mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:225,184,883...225,429,638
Ensembl chr 1:225,184,939...225,215,015
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases expression |
ISO |
Paraquat results in decreased expression of AHR protein |
CTD |
PMID:26196221 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [MTHFR gene polymorphism affects the susceptibility to Paraquat] which results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein] |
CTD |
PMID:28202386 PMID:30726997 PMID:32375810 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
AIFM1 protein inhibits the reaction [Paraquat results in decreased reduction of Glutathione]; AIFM1 protein promotes the reaction [Paraquat results in decreased reduction of Adenine Nucleotides] |
CTD |
PMID:15316071 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Ak1 |
adenylate kinase 1 |
increases expression |
ISO |
Paraquat results in increased expression of AK1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 3:11,652,143...11,659,135
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AKR1B3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of AKR1C3 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression affects phosphorylation multiple interactions |
ISO |
Paraquat results in decreased expression of AKT1 mRNA Paraquat affects the phosphorylation of AKT1 protein ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of AKT1 protein] [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; AKT1 protein affects the reaction [Paraquat results in decreased expression of BCL2 protein]; AKT1 protein affects the reaction [Paraquat results in increased activity of CASP3 protein]; AKT1 protein affects the reaction [Paraquat results in increased expression of BAX protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of AKT1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Paraquat results in increased expression of and results in increased phosphorylation of AKT1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA] |
CTD |
PMID:16797015 PMID:23898955 PMID:23963992 PMID:28115273 PMID:28428137 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions increases response to substance |
ISO |
AKT2 protein affects the reaction [Paraquat results in decreased expression of PPARGC1A protein]; AKT2 protein affects the reaction [Paraquat results in increased expression of NFE2L2 protein] AKT2 protein results in increased susceptibility to Paraquat |
CTD |
PMID:28115273 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases activity |
EXP |
Paraquat results in decreased activity of ALAD protein |
CTD |
PMID:12180188 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions increases activity |
EXP |
alpha-Tocopherol inhibits the reaction [Paraquat results in increased activity of ALAS1 protein] |
CTD |
PMID:12180188 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
Paraquat results in decreased expression of ALB protein |
CTD |
PMID:17481832 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
Paraquat results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
affects expression |
EXP |
Paraquat affects the expression of ALDH1A2 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
EXP |
Paraquat results in decreased expression of ALDH2 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Alkbh8 |
alkB homolog 8, tRNA methyltransferase |
increases expression |
ISO |
Paraquat results in increased expression of ALKBH8 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 6:18,877,885...18,952,773
Ensembl chr 6:18,877,907...18,949,393
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
increases expression |
ISO |
Paraquat results in increased expression of ALOX12B mRNA |
CTD |
PMID:28012437 |
|
NCBI chr10:55,744,646...55,756,524
Ensembl chr10:55,744,588...55,756,566
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions decreases expression |
ISO |
APOD protein affects the reaction [Paraquat results in decreased expression of ALOX15 mRNA]; Paraquat affects the reaction [APOD protein affects the expression of ALOX15 mRNA] |
CTD |
PMID:21688324 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Alox15b |
arachidonate 15-lipoxygenase, type B |
increases expression |
ISO |
Paraquat results in increased expression of ALOX8 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr10:55,773,748...55,783,489
Ensembl chr10:55,774,006...55,783,489
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
Paraquat results in increased expression of ALOX5 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Amh |
anti-Mullerian hormone |
decreases expression |
EXP |
Paraquat results in decreased expression of AMH mRNA |
CTD |
PMID:31128353 |
|
NCBI chr 7:11,775,155...11,777,503
Ensembl chr 7:11,775,155...11,777,503
|
|
G |
Amn |
amnion associated transmembrane protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AMN mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:135,724,455...135,731,896
Ensembl chr 6:135,724,455...135,731,896
|
|
G |
Amph |
amphiphysin |
decreases expression |
EXP |
Paraquat results in decreased expression of AMPH mRNA |
CTD |
PMID:18198484 |
|
NCBI chr17:48,304,324...48,562,838
Ensembl chr17:48,304,322...48,562,905
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
EXP |
Paraquat results in increased expression of ANXA1 protein |
CTD |
PMID:24521700 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
EXP |
Paraquat results in increased expression of ANXA2 protein |
CTD |
PMID:24521700 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
Paraquat results in increased expression of ANXA5 mRNA |
CTD |
PMID:20883675 |
|
NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:143,284,041...143,315,846
Ensembl chr 1:143,283,996...143,315,633
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression affects splicing increases expression |
ISO |
Paraquat results in decreased expression of APAF1 mRNA Paraquat affects the splicing of APAF1 exon Paraquat affects the splicing of APAF1 mRNA Paraquat results in increased expression of APAF1 mRNA alternative form |
CTD |
PMID:17064354 PMID:23613995 PMID:27111068 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:170,387,625...170,411,263
Ensembl chr 1:170,387,609...170,404,056
|
|
G |
Apeh |
acylaminoacyl-peptide hydrolase |
decreases response to substance |
ISO |
APEH protein results in decreased susceptibility to Paraquat |
CTD |
PMID:12727222 |
|
NCBI chr 8:116,862,664...116,871,776
Ensembl chr 8:116,862,625...116,872,215
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance affects response to substance |
ISO |
APEX1 gene mutant form results in increased susceptibility to Paraquat APEX1 gene SNP affects the susceptibility to Paraquat |
CTD |
PMID:11454706 PMID:28460087 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Apln |
apelin |
decreases expression |
ISO |
Paraquat results in decreased expression of APLN mRNA |
CTD |
PMID:32870474 |
|
NCBI chr X:134,856,719...134,866,210
Ensembl chr X:134,856,726...134,866,210
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
Paraquat affects the expression of and results in increased degradation of APOA1 mRNA |
CTD |
PMID:9169468 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Apod |
apolipoprotein D |
multiple interactions increases expression decreases response to substance affects response to substance |
ISO |
Paraquat results in increased uptake of and affects the localization of APOD protein; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD protein] APOD protein results in decreased susceptibility to Paraquat APOD protein affects the susceptibility to Paraquat [Paraquat co-treated with APOD gene mutant form] results in increased expression of NOS2 mRNA; APOD protein affects the reaction [Paraquat results in decreased expression of ALOX15 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of AQR mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of EPX mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of GAB1 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of GPX2 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of IDH1 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of LPO mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of NOS2 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of NOX4 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of NOXO1 mRNA]; APOD protein affects the reaction [Paraquat results in decreased expression of PTGS1 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of DUOX1 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of GDNF mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of GFAP protein]; APOD protein affects the reaction [Paraquat results in increased expression of GPX3 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of IL19 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of MPP4 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of PTGS2 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of SOD2 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of SOD3 mRNA]; APOD protein affects the reaction [Paraquat results in increased expression of SRXN1 mRNA]; APOD protein inhibits the reaction [Paraquat results in decreased activity of CTSB protein]; Paraquat affects the reaction [APOD protein affects the expression of ALOX15 mRNA]; Paraquat affects the reaction [APOD protein affects the expression of HMOX1 protein]; Paraquat affects the reaction [APOD protein affects the expression of SOD2 protein] Paraquat results in increased expression of APOD mRNA; Paraquat results in increased expression of APOD protein |
CTD |
PMID:18419796 PMID:18458334 PMID:21688324 PMID:28182653 |
|
NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
|
|
G |
App |
amyloid beta precursor protein |
increases response to substance multiple interactions increases expression |
ISO EXP |
APP protein results in increased susceptibility to Paraquat Estradiol inhibits the reaction [Paraquat results in increased expression of APP protein alternative form]; Estradiol inhibits the reaction [Paraquat results in increased expression of APP protein] Paraquat results in increased expression of APP protein; Paraquat results in increased expression of APP protein alternative form Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]; Curcumin inhibits the reaction [Paraquat results in increased expression of APP mRNA]; Curcumin inhibits the reaction [Paraquat results in increased expression of APP protein]; Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]; Paraquat promotes the reaction [APP protein binds to APP protein] Paraquat results in increased expression of APP mRNA; Paraquat results in increased expression of APP protein |
CTD |
PMID:23827522 PMID:27793699 PMID:31715309 PMID:33290254 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
decreases expression |
ISO |
Paraquat results in decreased expression of APRT mRNA |
CTD |
PMID:21371552 |
|
NCBI chr19:55,387,288...55,389,256
Ensembl chr19:55,387,288...55,389,256
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Paraquat results in increased expression of AQP1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqr |
aquarius intron-binding spliceosomal factor |
multiple interactions decreases expression |
ISO |
APOD protein affects the reaction [Paraquat results in decreased expression of AQR mRNA] |
CTD |
PMID:21688324 |
|
NCBI chr 3:105,570,399...105,640,431
Ensembl chr 3:105,570,292...105,640,463
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
affects expression |
EXP |
Paraquat affects the expression of ARF1 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:140,412,463...140,438,751
Ensembl chr 7:140,398,199...140,437,467
|
|
G |
Arf5 |
ADP-ribosylation factor 5 |
increases expression |
EXP |
Paraquat results in increased expression of ARF5 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 4:55,715,744...55,718,670
Ensembl chr 4:55,715,744...55,718,670
|
|
G |
Arg1 |
arginase 1 |
increases expression multiple interactions decreases expression |
EXP ISO |
Paraquat results in increased expression of ARG1 mRNA [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA Paraquat results in decreased expression of ARG1 protein Paraquat results in decreased expression of ARG1 mRNA |
CTD |
PMID:20388547 PMID:24521700 PMID:28467894 PMID:29568078 PMID:31299241 PMID:32375810 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arg2 |
arginase 2 |
increases expression |
EXP |
Paraquat results in increased expression of ARG2 mRNA |
CTD |
PMID:16854511 PMID:20388547 |
|
NCBI chr 6:102,311,097...102,338,406
Ensembl chr 6:102,311,116...102,338,520
|
|
G |
Arl2 |
ADP-ribosylation factor like GTPase 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of ARL2 protein |
CTD |
PMID:23807224 |
|
NCBI chr 1:221,504,150...221,516,191
Ensembl chr 1:221,504,170...221,516,110
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
affects response to substance increases expression multiple interactions |
ISO |
ARL6IP5 protein affects the susceptibility to Paraquat Paraquat results in increased expression of ARL6IP5 Paraquat results in increased expression of ARL6IP5 protein ARL6IP5 protein affects the reaction [Paraquat affects the expression of NFE2L2 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the expression of TH protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of AKT1 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of MAPK1 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of MAPK3 protein] ARL6IP5 protein affects the reaction [Paraquat affects the expression of NFE2L2 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of AKT1 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of MAPK1 protein]; ARL6IP5 protein affects the reaction [Paraquat affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:28428137 |
|
NCBI chr 4:129,574,363...129,598,240
Ensembl chr 4:129,574,264...129,598,915
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
increases expression |
ISO |
Paraquat results in increased expression of ART3 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr14:17,143,037...17,225,389
Ensembl chr14:17,143,040...17,225,389
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:28,038,662...28,040,504
Ensembl chr 7:28,038,662...28,040,510
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
affects expression increases expression |
EXP |
Paraquat affects the expression of ASIC1 mRNA Paraquat results in increased expression of ASIC1 mRNA |
CTD |
PMID:15206577 PMID:17077588 PMID:18198484 |
|
NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937
|
|
G |
Asic3 |
acid sensing ion channel subunit 3 |
increases expression |
EXP |
Paraquat results in increased expression of ACCN3 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 4:7,287,868...7,293,295
Ensembl chr 4:7,288,855...7,292,901
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Paraquat results in increased expression of ATF3 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Paraquat results in increased expression of ATF4 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression increases cleavage multiple interactions |
EXP ISO |
Paraquat results in increased expression of ATF6 protein Paraquat results in increased cleavage of ATF6 protein Paraquat results in increased expression of ATF6 protein modified form Minocycline inhibits the reaction [Paraquat results in increased expression of ATF6 protein] |
CTD |
PMID:22245251 PMID:28986289 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atg12 |
autophagy related 12 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of ATG12 protein Paraquat results in increased expression of ATG12 mRNA ATG5 protein affects the reaction [Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein]]; Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein] [Paraquat co-treated with Chlorpyrifos] results in increased expression of ATG12 protein; Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein]; Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein] |
CTD |
PMID:22292029 PMID:22982048 PMID:26884967 PMID:27220436 |
|
NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
increases expression |
ISO |
Paraquat results in increased expression of ATG4B mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atg5 |
autophagy related 5 |
affects response to substance increases expression multiple interactions |
ISO EXP |
ATG5 protein affects the susceptibility to Paraquat Paraquat results in increased expression of ATG5 mRNA [ATG5 protein affects the susceptibility to Paraquat] which affects the abundance of Lipofuscin; ATG5 protein affects the reaction [Paraquat results in increased expression of LAMP1 protein]; Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein]; TLR4 protein affects the reaction [Paraquat results in increased expression of ATG5 protein] Paraquat results in increased expression of ATG5 mRNA; Paraquat results in increased expression of ATG5 protein [ATG5 protein affects the susceptibility to Paraquat] which affects the abundance of Lipofuscin; ATG5 protein affects the reaction [Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein]]; ATG5 protein affects the reaction [Paraquat results in increased expression of LAMP1 protein]; ATG5 protein affects the reaction [Paraquat results in increased expression of MAP1LC3A protein]; ATG5 protein promotes the reaction [Paraquat results in increased cleavage of and results in increased activity of CASP3 protein]; Paraquat results in increased expression of [ATG5 protein binds to ATG12 protein]; WNT1 protein inhibits the reaction [Paraquat results in increased expression of ATG5 mRNA] |
CTD |
PMID:22982048 PMID:23997112 PMID:27220436 PMID:27246695 PMID:27324791 PMID:30171970 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
increases expression affects response to substance multiple interactions |
ISO |
Paraquat results in increased expression of ATG7 protein ATG7 protein affects the susceptibility to Paraquat Paraquat results in increased expression of ATG7 mRNA [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of AKR1C3 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of ATM mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BACH1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BARD1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BLM mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BRCA1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BUB1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BUB1B mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNA2 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNB1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNB2 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNE1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNE2 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDC20 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDC25C mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDK1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDK2 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDKN1A mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CHEK1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCA mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCB mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCD2 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of KIF11 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of KIF14 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of KIF23 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of NBN mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of PLK1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of PLK4 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of PRC1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of SMC1A mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of STAT1 mRNA; [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of TRP53 protein; ATG7 protein affects the reaction [Paraquat results in decreased expression of LMNB1 protein]; ATG7 protein affects the reaction [Paraquat results in increased expression of CDKN1A protein]; ATG7 protein affects the reaction [Paraquat results in increased expression of H2AX protein]; ATG7 protein affects the reaction [Paraquat results in increased expression of TRP53 mRNA]; Paraquat affects the reaction [ATG7 protein affects the expression of CDK1 mRNA]; Paraquat affects the reaction [ATG7 protein affects the expression of CDK1 protein]; Paraquat affects the reaction [ATG7 protein affects the expression of LMNB1 mRNA]; TLR4 protein affects the reaction [Paraquat results in increased expression of ATG7 protein] |
CTD |
PMID:27220436 PMID:27246695 PMID:28012437 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of ATM mRNA [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of ATM mRNA |
CTD |
PMID:20883675 PMID:28012437 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp13a2 |
ATPase cation transporting 13A2 |
multiple interactions increases response to substance |
ISO |
[ATP13A2 protein results in increased susceptibility to Paraquat] which results in increased abundance of Reactive Oxygen Species |
CTD |
PMID:22265822 |
|
NCBI chr 5:159,512,208...159,531,631
Ensembl chr 5:159,512,285...159,531,637
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Paraquat results in increased expression of ATP1A1 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
affects expression increases expression decreases expression |
EXP ISO |
Paraquat affects the expression of ATP1A2 mRNA Paraquat results in increased expression of ATP1A2 mRNA Paraquat results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:16854511 PMID:17077588 PMID:18198484 PMID:21371552 |
|
NCBI chr13:90,651,682...90,676,629
Ensembl chr13:90,651,686...90,676,629
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
affects expression increases expression |
EXP |
Paraquat affects the expression of ATP1B1 mRNA Paraquat results in increased expression of ATP1B1 mRNA |
CTD |
PMID:16555045 PMID:16854511 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions affects expression increases expression |
ISO EXP |
IGF1 gene mutant form inhibits the reaction [Paraquat results in increased expression of ATP2A2 protein] Paraquat affects the expression of ATP2A2 mRNA |
CTD |
PMID:16854511 PMID:17979500 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
decreases expression |
EXP |
Paraquat results in decreased expression of ATP2B2 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 4:145,704,779...145,948,997
Ensembl chr 4:145,703,046...146,016,325
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP5G1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:83,895,941...83,898,640
Ensembl chr10:83,895,947...83,898,527
|
|
G |
Atp6v0a1 |
ATPase H+ transporting V0 subunit a1 |
multiple interactions |
ISO |
ATP6V0A1 protein affects the reaction [Paraquat results in increased expression of MAP1LC3A protein] |
CTD |
PMID:22982048 |
|
NCBI chr10:88,914,264...88,967,736
Ensembl chr10:88,914,276...88,967,748
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:136,718,352...136,719,868
Ensembl chr 5:136,718,352...136,721,379
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
|
|
G |
Atp6v0e2 |
ATPase, H+ transporting V0 subunit e2 |
increases expression |
ISO |
Paraquat results in increased expression of ATP6V0E2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 4:78,168,117...78,171,265
Ensembl chr 4:78,168,117...78,171,265
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:77,678,853...77,716,658
Ensembl chr 7:77,678,968...77,716,408
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions increases response to substance |
ISO |
ATP7A protein promotes the reaction [Paraquat results in increased chemical synthesis of Hydrogen Peroxide] ATP7A protein results in increased susceptibility to Paraquat |
CTD |
PMID:29058724 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atxn1 |
ataxin 1 |
affects expression |
EXP |
Paraquat affects the expression of ATXN1 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr17:19,160,986...19,533,814
Ensembl chr17:19,249,952...19,533,814
|
|
G |
Atxn2 |
ataxin 2 |
affects splicing |
ISO |
Paraquat affects the splicing of ATXN2 exon |
CTD |
PMID:27111068 |
|
NCBI chr12:40,264,601...40,335,637
Ensembl chr12:40,266,662...40,332,612
|
|
G |
Aurka |
aurora kinase A |
affects expression |
ISO |
Paraquat affects the expression of AURKA mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Paraquat results in increased expression of AVP mRNA; Paraquat results in increased expression of AVP protein |
CTD |
PMID:30744883 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Avpr1b |
arginine vasopressin receptor 1B |
decreases expression |
EXP |
Paraquat results in decreased expression of AVPR1B mRNA |
CTD |
PMID:17077588 |
|
NCBI chr13:48,367,307...48,378,831
Ensembl chr13:48,367,307...48,378,831
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
decreases expression |
EXP |
Paraquat results in decreased expression of AVPR2 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr X:156,889,006...156,892,707
Ensembl chr X:156,889,410...156,891,213
|
|
G |
Axin1 |
axin 1 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of AXIN1 mRNA; Paraquat results in decreased expression of AXIN1 protein WNT1 protein inhibits the reaction [Paraquat results in decreased expression of AXIN1 mRNA] |
CTD |
PMID:30171970 |
|
|
|
G |
Axin2 |
axin 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of AXIN2 mRNA |
CTD |
PMID:27788593 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BACH1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions increases expression decreases expression |
ISO EXP |
[Paraquat co-treated with Maneb] results in increased phosphorylation of BAD protein TLR4 gene mutant form inhibits the reaction [Paraquat results in increased expression of BAD protein] Paraquat results in decreased expression of BAD mRNA Paraquat results in increased expression of BAD mRNA |
CTD |
PMID:15824117 PMID:17935786 PMID:18836921 PMID:27442881 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
increases expression |
ISO |
Paraquat results in increased expression of BAG1 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bag4 |
BAG cochaperone 4 |
increases expression |
ISO |
Paraquat results in increased expression of BAG4 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr16:71,057,709...71,075,874
Ensembl chr16:71,058,022...71,075,320
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression multiple interactions affects response to substance decreases expression |
ISO EXP |
Paraquat results in increased expression of BAK1 mRNA; Paraquat results in increased expression of BAK1 protein [Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; LGK974 inhibits the reaction [Paraquat results in increased expression of BAK1 protein]; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb] [Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA] Paraquat results in decreased expression of BAK1 mRNA NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of BAK1 mRNA]; Paraquat promotes the reaction [BAX protein binds to BAK1 protein] |
CTD |
PMID:18056701 PMID:18266926 PMID:18836921 PMID:22230393 PMID:22678742 PMID:23963992 PMID:25947082 PMID:30205152 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BARD1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects expression increases expression decreases expression |
ISO EXP |
[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; AKT1 protein affects the reaction [Paraquat results in increased expression of BAX protein]; GPX1 protein affects the reaction [Paraquat affects the expression of BAX mRNA]; Lithium Chloride inhibits the reaction [Paraquat results in increased expression of BAX protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [Paraquat results in increased expression of BAX protein]; TO-901317 inhibits the reaction [Paraquat results in increased expression of BAX protein] Paraquat results in increased expression of BAX mRNA; Paraquat results in increased expression of BAX protein [Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb]; Curcumin inhibits the reaction [Paraquat results in increased expression of BAX protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in increased expression of BAX protein]; salvin inhibits the reaction [Paraquat results in increased expression of BAX protein]; WNT1 protein inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; WNT1 protein inhibits the reaction [Paraquat results in increased expression of BAX protein] Paraquat results in decreased expression of BAX mRNA [Paraquat co-treated with Decitabine] results in increased expression of BAX protein; Anthocyanins inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; Anthocyanins inhibits the reaction [Paraquat results in increased expression of BAX protein]; Docosahexaenoic Acids inhibits the reaction [Paraquat results in increased expression of BAX protein]; fasudil inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; Paraquat promotes the reaction [BAX protein binds to BAK1 protein]; Paraquat results in increased expression of and affects the localization of BAX protein |
CTD |
PMID:12654481 PMID:12714668 PMID:15206577 PMID:15824117 PMID:18253895 PMID:18266926 PMID:18836921 PMID:20964710 PMID:22678742 PMID:22796470 PMID:23963992 PMID:25947082 PMID:26468117 PMID:26686574 PMID:26887261 PMID:27220436 PMID:27442881 PMID:27793699 PMID:28115273 PMID:28480221 PMID:29054699 PMID:30088170 PMID:30171970 PMID:30185695 PMID:30403199 PMID:31128353 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Paraquat results in increased expression of BBC3 protein |
CTD |
PMID:18266926 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
Paraquat results in decreased activity of BCHE protein |
CTD |
PMID:17364237 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bckdhb |
branched chain keto acid dehydrogenase E1 subunit beta |
increases expression |
ISO |
Paraquat results in increased expression of BCKDHB mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 8:91,464,229...91,656,134
Ensembl chr 8:91,464,229...91,656,134
|
|
G |
Bcl10 |
BCL10, immune signaling adaptor |
decreases expression |
ISO |
Paraquat results in decreased expression of BCL10 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 2:251,805,392...251,814,957
Ensembl chr 2:251,805,392...251,814,957
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression decreases response to substance increases expression |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; AKT1 protein affects the reaction [Paraquat results in decreased expression of BCL2 protein]; GPX1 protein affects the reaction [Paraquat affects the expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; TO-901317 inhibits the reaction [Paraquat results in decreased expression of BCL2 protein] Paraquat results in decreased expression of BCL2 mRNA; Paraquat results in decreased expression of BCL2 protein Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; WNT1 protein inhibits the reaction [Paraquat results in decreased expression of BCL2 protein] BCL2 protein results in decreased susceptibility to Paraquat Paraquat results in increased expression of BCL2 mRNA [Paraquat co-treated with Decitabine] results in decreased expression of BCL2 protein; Anthocyanins inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA]; Anthocyanins inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; Docosahexaenoic Acids inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; fasudil inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA]; NFE2L2 mutant form inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA] |
CTD |
PMID:12654481 PMID:12714668 PMID:15475374 PMID:18836921 PMID:22230393 PMID:22678742 PMID:22796470 PMID:23963992 PMID:26468117 PMID:26686574 PMID:26887261 PMID:27220436 PMID:28115273 PMID:28480221 PMID:29054699 PMID:30088170 PMID:30171970 PMID:30185695 PMID:30403199 PMID:30698896 PMID:31128353 PMID:31400064 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
decreases expression multiple interactions increases expression |
ISO |
Paraquat results in decreased expression of BCL2A1 mRNA [Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein Paraquat results in increased expression of BCL2A1 mRNA; Paraquat results in increased expression of BCL2A1 protein |
CTD |
PMID:18056701 PMID:18266926 PMID:18836921 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression affects expression decreases response to substance |
ISO EXP |
[Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein Paraquat results in increased expression of BCL2L1 mRNA; Paraquat results in increased expression of BCL2L1 protein Paraquat results in decreased expression of BCL2L1 mRNA Paraquat affects the expression of BCL2L1 mRNA BCL2L1 gene mutant form results in decreased susceptibility to Paraquat GPX1 protein affects the reaction [Paraquat results in increased expression of BCL2L1 protein] |
CTD |
PMID:10970895 PMID:12595580 PMID:12654481 PMID:15824117 PMID:16797015 PMID:16854511 PMID:18056701 PMID:18836921 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l10 |
BCL2 like 10 |
decreases expression |
ISO |
Paraquat results in decreased expression of BCL2L10 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 8:82,288,705...82,294,750
Ensembl chr 8:82,288,705...82,294,744
|
|
G |
Bcl2l11 |
BCL2 like 11 |
decreases expression multiple interactions increases expression |
ISO |
Paraquat results in decreased expression of BCL2L11 mRNA [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein Paraquat results in increased expression of BCL2L11 protein Paraquat results in increased expression of BCL2L11 mRNA FOXO3 mutant form inhibits the reaction [Paraquat results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:18266926 PMID:18836921 PMID:23620592 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
multiple interactions |
ISO |
GPX1 protein affects the reaction [Paraquat affects the expression of BCL2L2 mRNA] |
CTD |
PMID:12654481 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of BCLAF1 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 1:15,799,753...15,828,838
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions decreases expression increases expression |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA; LRRK2 protein mutant form promotes the reaction [Paraquat results in decreased expression of BDNF protein] Paraquat results in increased expression of BDNF mRNA [Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein |
CTD |
PMID:23017109 PMID:27460631 PMID:29454966 PMID:31174552 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression increases expression |
ISO |
[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; WNT1 protein inhibits the reaction [Paraquat results in increased expression of BECN1 mRNA] [Paraquat co-treated with Chlorpyrifos] results in increased expression of BECN1 protein; [Paraquat co-treated with Maneb] results in increased expression of BECN1 protein Paraquat results in increased expression of BECN1 mRNA; Paraquat results in increased expression of BECN1 protein |
CTD |
PMID:20929985 PMID:22292029 PMID:25092649 PMID:26884967 PMID:27220436 PMID:30171970 PMID:32306690 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bfar |
bifunctional apoptosis regulator |
increases expression |
ISO |
Paraquat results in increased expression of BFAR mRNA |
CTD |
PMID:18836921 |
|
NCBI chr10:1,464,658...1,471,152 NCBI chr10:1,464,783...1,497,653
Ensembl chr10:1,464,765...1,497,653
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of BICD1 mRNA [Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression multiple interactions increases expression increases cleavage |
ISO |
Paraquat results in decreased expression of BID mRNA [Maneb co-treated with Paraquat] results in increased expression of BID protein Paraquat results in increased expression of BID mRNA; Paraquat results in increased expression of BID protein Paraquat results in increased cleavage of BID protein |
CTD |
PMID:18056701 PMID:18266926 PMID:18836921 PMID:28414160 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bik |
BCL2-interacting killer |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of BIK mRNA [Paraquat co-treated with Maneb] results in increased expression of BIK protein |
CTD |
PMID:18266926 PMID:18836921 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bin1 |
bridging integrator 1 |
affects splicing |
ISO |
Paraquat affects the splicing of BIN1 mRNA |
CTD |
PMID:23613995 |
|
NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of BIRC2 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Paraquat results in decreased expression of BIRC3 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression decreases expression |
ISO EXP |
Paraquat results in increased expression of BIRC5 mRNA Paraquat results in decreased expression of BIRC5 mRNA |
CTD |
PMID:26345256 PMID:26887261 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Blm |
BLM RecQ like helicase |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BLM mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 1:142,246,773...142,332,616
Ensembl chr 1:142,246,790...142,332,588
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions decreases expression |
ISO EXP |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA Paraquat results in decreased expression of BMP4 mRNA |
CTD |
PMID:18198484 PMID:23017109 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of BNIP1 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr10:16,677,077...16,689,321
Ensembl chr10:16,677,077...16,689,321
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression affects response to substance increases expression |
ISO |
Paraquat results in decreased expression of BNIP3 mRNA BNIP3 protein affects the susceptibility to Paraquat Paraquat results in increased expression of BNIP3 protein Paraquat results in increased expression of BNIP3 mRNA; Paraquat results in increased expression of BNIP3 protein |
CTD |
PMID:18056701 PMID:18266926 PMID:18836921 PMID:23315990 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Paraquat results in increased expression of BNIP3L mRNA |
CTD |
PMID:18836921 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
increases expression |
ISO |
Paraquat results in increased expression of BOP1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 7:117,514,529...117,538,342
Ensembl chr 7:117,514,533...117,538,342
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases response to substance multiple interactions |
ISO |
BRCA1 protein results in decreased susceptibility to Paraquat [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BRCA1 mRNA |
CTD |
PMID:15520196 PMID:28012437 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression |
ISO |
Paraquat results in decreased expression of BRCA2 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:137,762,230...137,808,573
Ensembl chr 6:137,765,122...137,808,303
|
|
G |
Bsg |
basigin (Ok blood group) |
increases expression |
ISO |
Paraquat results in increased expression of BSG protein |
CTD |
PMID:29287252 |
|
NCBI chr 7:12,875,536...12,882,753
Ensembl chr 7:12,875,537...12,882,753
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
increases expression |
EXP |
Paraquat results in increased expression of BST1 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr14:71,798,218...71,814,540
Ensembl chr14:71,798,651...71,814,523
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Paraquat results in increased expression of BTG2 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BUB1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of BUB1B mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
|
|
G |
Ca3 |
carbonic anhydrase 3 |
affects expression |
EXP |
Paraquat affects the expression of CAR3 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases expression |
EXP |
Paraquat results in increased expression of CACNA1C mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA Paraquat results in increased expression of CACNA1E mRNA |
CTD |
PMID:22563483 |
|
NCBI chr13:71,899,445...72,534,992
Ensembl chr13:71,906,702...72,367,980
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
increases expression |
EXP |
Paraquat results in increased expression of CACNB3 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 7:140,311,120...140,324,902
Ensembl chr 7:140,315,368...140,324,902
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA Paraquat results in increased expression of CACYBP mRNA |
CTD |
PMID:18386188 PMID:28619522 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Calcr |
calcitonin receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of CALCR mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 4:28,627,439...28,702,559
Ensembl chr 4:28,627,442...28,702,559
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions increases expression |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA] Paraquat results in increased expression of CALM1 mRNA |
CTD |
PMID:23963992 PMID:31368498 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Calm2 |
calmodulin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
multiple interactions |
ISO EXP |
[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA [Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA |
CTD |
PMID:22563483 PMID:27460631 |
|
NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
|
|
G |
Capn1 |
calpain 1 |
multiple interactions increases activity |
EXP ISO |
Paraquat results in increased expression of and results in increased activity of CAPN1 protein calpeptin inhibits the reaction [Paraquat results in increased activity of CAPN1 protein] |
CTD |
PMID:22678742 PMID:24509835 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Capn11 |
calpain 11 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:17,728,845...17,750,357
Ensembl chr 9:17,728,816...17,750,363
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
EXP |
Paraquat results in increased expression of and results in increased activity of CAPN2 protein |
CTD |
PMID:22678742 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Capn6 |
calpain 6 |
increases expression |
ISO |
Paraquat results in increased expression of CAPN6 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr X:115,049,113...115,073,824
Ensembl chr X:115,049,154...115,073,890
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
EXP |
Paraquat results in increased expression of CAR2 protein |
CTD |
PMID:24521700 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Card6 |
caspase recruitment domain family, member 6 |
decreases expression |
ISO |
Paraquat results in decreased expression of CARD6 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 2:54,810,676...54,824,050
Ensembl chr 2:54,810,110...54,824,033
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression decreases activity |
EXP ISO |
Glyburide inhibits the reaction [Paraquat results in increased expression of CASP1 protein]; procyanidin B2 inhibits the reaction [Paraquat results in increased expression of CASP1 protein]; Sodium Salicylate inhibits the reaction [Paraquat results in decreased activity of CASP1 protein] Paraquat results in increased expression of CASP1 protein; Paraquat results in increased expression of CASP1 protein modified form Paraquat results in increased expression of CASP1 mRNA; Paraquat results in increased expression of CASP1 protein [Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [Paraquat results in increased expression of CASP1 protein modified form]; Silymarin inhibits the reaction [Paraquat results in increased expression of CASP1 protein] |
CTD |
PMID:17561093 PMID:18836921 PMID:23963992 PMID:25338942 PMID:29054699 PMID:30025709 PMID:32375810 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp12 |
caspase 12 |
multiple interactions increases activity increases expression increases degradation |
EXP |
Minocycline results in decreased degradation of [Paraquat results in increased expression of CASP12 protein]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of CASP12 mRNA] Paraquat results in increased activity of CASP12 protein Paraquat results in increased expression of CASP12 mRNA; Paraquat results in increased expression of CASP12 protein Paraquat results in increased degradation of CASP12 protein |
CTD |
PMID:22245251 PMID:22678742 PMID:24912633 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp2 |
caspase 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of CASP2 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity decreases expression increases cleavage |
ISO EXP |
AKT1 protein affects the reaction [Paraquat results in increased activity of CASP3 protein]; GPX1 protein affects the reaction [Paraquat results in increased activity of CASP3 protein]; GPX1 protein affects the reaction [Paraquat results in increased expression of CASP3 protein]; PARK7 protein affects the reaction [Paraquat results in increased cleavage of CASP3 protein]; Silymarin inhibits the reaction [Paraquat results in increased expression of CASP3 protein modified form] Paraquat results in increased expression of CASP3 mRNA; Paraquat results in increased expression of CASP3 protein modified form Paraquat results in decreased expression of CASP3 mRNA Paraquat results in increased expression of CASP3 mRNA; Paraquat results in increased expression of CASP3 protein; Paraquat results in increased expression of CASP3 protein modified form 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]]; 3-methyladenine promotes the reaction [Paraquat results in increased activity of CASP3 protein]; [Mifepristone co-treated with NFE2L2 protein] inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA]; [PTGDS protein results in decreased susceptibility to Paraquat] which results in decreased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; ATG5 protein promotes the reaction [Paraquat results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; CAT protein inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; GHRL protein inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; LGK974 inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; Paraquat promotes the reaction [Trientine results in increased activity of CASP3 protein]; Paraquat results in increased cleavage of and results in increased activity of CASP3 protein; PRKN protein inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; PTGDS mutant form promotes the reaction [Paraquat results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of CASP3 protein modified form]; salubrinal inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; TLR9 protein promotes the reaction [Paraquat results in increased expression of CASP3 protein modified form] Acetylcysteine inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; calpeptin inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; Cyclosporine inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; Dibucaine inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; diphenyleneiodonium inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; Edaravone inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA]; Minocycline inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; Sodium Salicylate inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; U 74389F inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein] |
CTD |
PMID:11369509 PMID:12654481 PMID:16310883 PMID:17018646 PMID:17215068 PMID:17324951 PMID:17341480 PMID:17561093 PMID:17936647 PMID:18056701 PMID:18253895 PMID:18836921 PMID:19735704 PMID:20929985 PMID:21300143 PMID:21777615 PMID:22043816 PMID:22245251 PMID:22678742 PMID:22736252 PMID:22987761 PMID:23807224 PMID:23997112 PMID:24060684 PMID:24130211 PMID:24866057 PMID:24912633 PMID:25947082 PMID:26468117 PMID:26686574 PMID:27442881 PMID:28115273 PMID:28363843 PMID:28414160 PMID:28428137 PMID:28474156 PMID:28986289 PMID:29054699 PMID:30088170 PMID:30144575 PMID:30185695 PMID:30205152 PMID:30698896 PMID:30967525 PMID:31381934 PMID:31400064 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions increases expression |
EXP ISO |
Paraquat results in increased activity of CASP7 protein CAT protein inhibits the reaction [Paraquat results in increased activity of CASP7 protein] Paraquat results in increased expression of CASP7 mRNA NFE2L2 mutant form inhibits the reaction [Paraquat results in increased activity of CASP7 protein] |
CTD |
PMID:17324951 PMID:18836921 PMID:22678742 PMID:24866057 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases expression increases cleavage multiple interactions decreases expression increases activity |
ISO EXP |
Paraquat results in increased expression of CASP8 mRNA; Paraquat results in increased expression of CASP8 mRNA alternative form Paraquat results in increased cleavage of CASP8 protein 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in increased expression of CASP8 protein modified form]; Paraquat promotes the reaction [TNFRSF10B protein binds to CASP8 protein] Paraquat results in decreased expression of CASP8 mRNA Paraquat results in increased activity of CASP8 protein Sodium Salicylate inhibits the reaction [Paraquat results in increased activity of CASP8 protein] |
CTD |
PMID:17064354 PMID:17561093 PMID:20883675 PMID:24912633 PMID:26468117 PMID:28414160 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions increases activity decreases expression increases cleavage |
ISO EXP |
Paraquat results in increased expression of CASP9 mRNA; Paraquat results in increased expression of CASP9 mRNA alternative form; Paraquat results in increased expression of CASP9 protein Paraquat results in increased expression of CASP9 protein modified form [Mifepristone co-treated with NFE2L2 protein] inhibits the reaction [Paraquat results in increased expression of CASP9 mRNA]; [PTGDS protein results in decreased susceptibility to Paraquat] which results in decreased cleavage of CASP9 protein; PRKN protein inhibits the reaction [Paraquat results in increased activity of CASP9 protein]; PTGDS mutant form promotes the reaction [Paraquat results in increased cleavage of CASP9 protein]; salvin inhibits the reaction [Paraquat results in increased activity of CASP9 protein] Paraquat results in decreased expression of CASP9 mRNA [Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein] |
CTD |
PMID:17064354 PMID:18253895 PMID:18836921 PMID:20964710 PMID:22043816 PMID:22736252 PMID:23963992 PMID:24912633 PMID:26649146 PMID:26686574 PMID:27442881 PMID:30144575 PMID:30698896 PMID:31400064 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
affects response to substance decreases expression affects activity decreases activity increases expression increases activity multiple interactions decreases response to substance increases response to substance |
ISO EXP |
CAT protein affects the susceptibility to Paraquat Paraquat results in decreased expression of CAT protein Paraquat affects the activity of CAT protein Paraquat results in decreased activity of CAT protein Paraquat results in increased expression of CAT mRNA; Paraquat results in increased expression of CAT protein Paraquat results in increased activity of CAT protein [Maneb co-treated with Paraquat] results in increased expression of CAT mRNA; [Mifepristone co-treated with Paraquat] results in decreased activity of CAT protein; [Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of CAT mRNA; [Prednisolone co-treated with pirfenidone] inhibits the reaction [Paraquat results in decreased activity of CAT protein]; betanin inhibits the reaction [Paraquat results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Paraquat results in decreased activity of CAT protein]; embelin inhibits the reaction [Paraquat results in decreased expression of CAT protein]; NFE2L2 protein inhibits the reaction [[Mifepristone co-treated with Paraquat] results in decreased activity of CAT protein]; Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of CAT protein]; pirfenidone inhibits the reaction [Paraquat results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Paraquat results in increased activity of CAT protein]; Unithiol promotes the reaction [Paraquat results in increased activity of CAT protein]; Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of CAT protein] Paraquat results in decreased expression of CAT mRNA; Paraquat results in decreased expression of CAT protein CAT protein results in decreased susceptibility to Paraquat Curcumin inhibits the reaction [Paraquat results in decreased activity of CAT protein]; Hydroxylamine inhibits the reaction [CAT protein results in decreased susceptibility to Paraquat]; NFKB1 protein mutant form inhibits the reaction [Paraquat results in increased expression of CAT mRNA]; NFKBIA protein mutant form inhibits the reaction [Paraquat results in increased expression of CAT mRNA]; pirfenidone inhibits the reaction [Paraquat results in increased activity of CAT protein]; Resveratrol inhibits the reaction [Paraquat results in decreased activity of CAT protein]; SIRT1 protein affects the reaction [Paraquat affects the activity of CAT protein]; TO-901317 inhibits the reaction [Paraquat results in decreased activity of CAT protein] [Mifepristone co-treated with NFE2L2 protein] inhibits the reaction [Paraquat results in decreased activity of CAT protein]; [NR1I2 protein results in decreased activity of CAT protein] which results in increased susceptibility to Paraquat; [Paraquat co-treated with Thioctic Acid] results in increased expression of CAT mRNA; [Plant Extracts co-treated with Paraquat] results in increased expression of CAT mRNA; [SOD1 protein co-treated with CAT protein] results in decreased susceptibility to Paraquat; CAT protein inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [Paraquat results in decreased expression of GCLC protein]; CAT protein inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; CAT protein inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; CAT protein inhibits the reaction [Paraquat results in increased activity of CASP7 protein]; CAT protein inhibits the reaction [Paraquat results in increased activity of ODC1 protein]; CAT protein inhibits the reaction [Paraquat results in increased expression of JUN mRNA]; CAT protein inhibits the reaction [Paraquat results in increased expression of MIR153 mRNA]; Dimethyl Sulfoxide inhibits the reaction [Paraquat results in increased expression of CAT mRNA]; IL1A protein promotes the reaction [Paraquat results in increased expression of CAT protein]; IL1B protein promotes the reaction [Paraquat results in increased expression of CAT protein]; Plant Extracts promotes the reaction [Paraquat results in increased expression of CAT mRNA]; TNF protein promotes the reaction [Paraquat results in increased expression of CAT protein] CAT protein modified form results in increased susceptibility to Paraquat; CAT protein results in increased susceptibility to Paraquat |
CTD |
PMID:7662713 PMID:8317554 PMID:9169468 PMID:10699569 PMID:10751631 PMID:10754530 PMID:10959798 PMID:11178967 PMID:11325355 PMID:11728812 PMID:12180188 PMID:12826488 PMID:14759608 PMID:15177642 PMID:15190189 PMID:15754033 PMID:16195250 PMID:16677106 PMID:17107770 PMID:17215068 PMID:17935786 PMID:18620719 PMID:19486935 PMID:20095329 PMID:20553223 PMID:20883675 PMID:21215309 PMID:22736252 PMID:23649336 PMID:24141985 PMID:24376630 PMID:24799198 PMID:24812154 PMID:24866057 PMID:25169090 PMID:25461551 PMID:26468117 PMID:26598004 PMID:26649146 PMID:26708779 PMID:26935021 PMID:27993944 PMID:28480221 PMID:28696894 PMID:28921394 PMID:29273418 PMID:29859004 PMID:30243747 PMID:30744883 PMID:32020686 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
EXP |
Paraquat results in increased expression of CAV1 mRNA; Paraquat results in increased expression of CAV1 protein |
CTD |
PMID:26813466 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cbl |
Cbl proto-oncogene |
multiple interactions increases phosphorylation |
EXP |
CBL protein affects the reaction [Paraquat results in decreased expression of PDGFRA protein] Paraquat results in increased phosphorylation of CBL protein |
CTD |
PMID:17298174 |
|
NCBI chr 8:48,481,256...48,564,775
Ensembl chr 8:48,489,036...48,564,722
|
|
G |
Ccdc88a |
coiled coil domain containing 88A |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA Paraquat results in increased expression of CCDC88A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:113,771,093...113,936,376
Ensembl chr14:113,867,209...113,932,263
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of CCKBR mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA Paraquat results in increased expression of CCL19 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:58,181,025...58,182,969
Ensembl chr 5:58,181,026...58,183,017
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions affects expression increases expression |
EXP ISO |
[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CCL2 protein; Ambroxol affects the reaction [Paraquat results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CCL2 protein] Paraquat affects the expression of CCL2 mRNA |
CTD |
PMID:16324872 PMID:21921364 PMID:24376630 PMID:26345256 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of CCL20 protein PTPN6 protein inhibits the reaction [Paraquat results in increased expression of CCL20 protein] |
CTD |
PMID:18441283 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA Paraquat results in increased expression of CCL21 mRNA; Paraquat results in increased expression of CCL21A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:58,197,678...58,198,782
Ensembl chr 5:58,197,680...58,198,782
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Paraquat results in increased expression of CCL3 mRNA]; Dapsone inhibits the reaction [Paraquat results in increased expression of CCL3 mRNA] |
CTD |
PMID:16324872 PMID:21765237 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
Paraquat results in increased expression of CCN1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases secretion increases expression |
ISO EXP |
[CCN2 protein co-treated with Paraquat] affects the expression of MMP2 mRNA; [CCN2 protein co-treated with Paraquat] affects the expression of MMP9 mRNA; [CCN2 protein co-treated with Paraquat] affects the expression of TIMP1 mRNA; [Paraquat co-treated with TGFB1 protein] results in increased expression of CCN2 mRNA; Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Saralasin inhibits the reaction [Paraquat results in increased expression of CCN2 protein]; TGFB1 protein promotes the reaction [Paraquat results in increased expression of CCN2 protein]; Triamcinolone Acetonide promotes the reaction [Paraquat results in increased expression of CCN2 mRNA] Paraquat results in increased secretion of CCN2 protein ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of CCN2 protein] Paraquat results in increased expression of CCN2 mRNA; Paraquat results in increased expression of CCN2 protein LY2109761 inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; LY2109761 inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]; prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of CCN2 protein]; Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein] |
CTD |
PMID:12595580 PMID:15728566 PMID:16767377 PMID:20035857 PMID:23433149 PMID:25815693 PMID:25945502 PMID:26129822 PMID:26758514 PMID:27682480 PMID:33000210 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNA2 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNB1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNB2 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccnc |
cyclin C |
increases expression |
ISO |
Paraquat results in increased expression of CCNC mRNA |
CTD |
PMID:20883675 |
|
NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706
|
|
G |
Ccnd1 |
cyclin D1 |
affects expression multiple interactions decreases expression |
EXP ISO |
Paraquat affects the expression of CCND1 mRNA [Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA LGK974 inhibits the reaction [Paraquat results in decreased expression of CCND1 protein]; WNT1 protein inhibits the reaction [Paraquat results in decreased expression of CCND1 mRNA] |
CTD |
PMID:16854511 PMID:26887261 PMID:29859004 PMID:30171970 PMID:30205152 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
EXP ISO |
Paraquat results in decreased expression of CCND2 mRNA [Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA |
CTD |
PMID:17935786 PMID:28619522 PMID:29859004 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
EXP |
Paraquat results in decreased expression of CCND3 mRNA |
CTD |
PMID:17935786 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNE1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CCNE2 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
Paraquat results in increased expression of CCNG1 mRNA |
CTD |
PMID:17935786 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases response to substance |
ISO |
CCS gene mutant form results in increased susceptibility to Paraquat |
CTD |
PMID:10694572 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Paraquat results in increased expression of CD14 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Paraquat results in decreased expression of CD27 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
|
|
G |
Cd38 |
CD38 molecule |
decreases expression |
EXP |
Paraquat results in decreased expression of CD38 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
Paraquat results in increased expression of CD40 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
decreases expression |
EXP |
Paraquat results in decreased expression of CD44 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd47 |
Cd47 molecule |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of CD47 protein Paraquat results in increased expression of CD47 mRNA; Paraquat results in increased expression of CD47 protein THBS1 protein affects the reaction [Paraquat results in increased expression of CD47 protein] |
CTD |
PMID:29287252 PMID:30419666 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of CD68 mRNA [MTHFR gene polymorphism affects the susceptibility to Paraquat] which results in increased expression of CD68 protein; [Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA] |
CTD |
PMID:21371552 PMID:30726997 PMID:32169474 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cd70 |
Cd70 molecule |
decreases expression |
ISO |
Paraquat results in decreased expression of CD70 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
EXP |
Paraquat results in increased expression of CD80 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd86 |
CD86 molecule |
increases expression decreases expression |
EXP ISO |
Paraquat results in increased expression of CD86 mRNA Paraquat results in increased expression of CD86 protein Paraquat results in decreased expression of CD86 mRNA |
CTD |
PMID:24521700 PMID:28467894 PMID:31299241 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cd8b |
CD8b molecule |
decreases expression |
ISO |
Paraquat results in decreased expression of CD8B mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 4:99,185,960...99,201,887
Ensembl chr 4:99,185,885...99,202,023
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression multiple interactions increases expression |
EXP ISO |
Paraquat results in decreased expression of CDC20 mRNA [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDC20 mRNA Paraquat results in increased expression of CDC20 mRNA |
CTD |
PMID:18198484 PMID:26345256 PMID:28012437 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdc25a |
cell division cycle 25A |
affects expression |
EXP |
Paraquat affects the expression of CDC25A mRNA |
CTD |
PMID:16854511 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
Paraquat results in decreased expression of CDC25B mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDC25C mRNA |
CTD |
PMID:28012437 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdc40 |
cell division cycle 40 |
increases expression |
ISO |
Paraquat results in increased expression of CDC40 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr20:48,503,973...48,574,546
Ensembl chr20:48,503,973...48,574,546
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression multiple interactions |
EXP |
Paraquat results in decreased expression of CDH1 mRNA; Paraquat results in decreased expression of CDH1 protein Anthocyanins inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; sulforafan inhibits the reaction [Paraquat results in decreased expression of CDH1 protein] |
CTD |
PMID:25873302 PMID:28624451 PMID:30317802 PMID:30403199 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdhr4 |
cadherin-related family member 4 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of CDHR4 mRNA [Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:116,771,377...116,779,242
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:198,409,186...198,413,497
Ensembl chr 1:198,409,360...198,413,497
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDK1 mRNA; Paraquat affects the reaction [ATG7 protein affects the expression of CDK1 mRNA]; Paraquat affects the reaction [ATG7 protein affects the expression of CDK1 protein] Paraquat results in decreased expression of CDK1 mRNA; Paraquat results in decreased expression of CDK1 protein |
CTD |
PMID:28012437 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDK2 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA] |
CTD |
PMID:23963992 PMID:28012437 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdk5rap1 |
CDK5 regulatory subunit associated protein 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:149,835,953...149,870,429
Ensembl chr 3:149,703,848...149,870,413
|
|
G |
Cdk5rap2 |
CDK5 regulatory subunit associated protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] |
CTD |
PMID:23017109 |
|
NCBI chr 5:86,387,238...86,554,108
Ensembl chr 5:86,387,078...86,554,102
|
|
G |
Cdk8 |
cyclin-dependent kinase 8 |
decreases expression |
ISO |
Paraquat results in decreased expression of CDK8 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr12:10,496,273...10,561,335
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions decreases expression |
ISO |
Paraquat results in increased expression of CDKN1A mRNA; Paraquat results in increased expression of CDKN1A protein [ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CDKN1A mRNA; [Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; ATG7 protein affects the reaction [Paraquat results in increased expression of CDKN1A protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA] Paraquat results in decreased expression of CDKN1A mRNA |
CTD |
PMID:12595580 PMID:20883675 PMID:21371552 PMID:23963992 PMID:24060684 PMID:28012437 PMID:31368498 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
Paraquat results in decreased expression of CDKN1C mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
EXP |
Paraquat results in increased expression of CDKN2A mRNA [Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA |
CTD |
PMID:29859004 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
increases expression |
ISO |
Paraquat results in increased expression of CDKN2C mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
affects expression |
EXP |
Paraquat affects the expression of CDO1 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr18:40,702,027...40,716,901
Ensembl chr18:40,701,984...40,716,686
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
Paraquat results in increased expression of CEBPB mRNA |
CTD |
PMID:12595580 PMID:23613995 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of CEBPD mRNA [Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA |
CTD |
PMID:22563483 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Cep290 |
centrosomal protein 290 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA Paraquat results in increased expression of CEP290 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:40,217,269...40,306,327
Ensembl chr 7:40,217,269...40,306,327
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
EXP |
Paraquat results in increased expression of CFL1 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects expression affects splicing |
EXP ISO |
Paraquat affects the expression of CFTR mRNA Paraquat affects the splicing of CFTR exon |
CTD |
PMID:15206577 PMID:27111068 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chat |
choline O-acetyltransferase |
decreases activity decreases expression |
EXP |
Paraquat results in decreased activity of CHAT protein Paraquat results in decreased expression of CHAT mRNA |
CTD |
PMID:24521700 PMID:28916328 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of CHEK1 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chrna5 |
cholinergic receptor nicotinic alpha 5 subunit |
affects expression |
EXP |
Paraquat affects the expression of CHRNA5 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 8:59,561,817...59,590,172
Ensembl chr 8:59,561,721...59,590,172
|
|
G |
Chrna6 |
cholinergic receptor nicotinic alpha 6 subunit |
multiple interactions affects expression |
ISO EXP |
Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]]; Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein] Paraquat affects the expression of CHRNA6 mRNA |
CTD |
PMID:17227438 PMID:18198484 |
|
NCBI chr16:68,860,018...68,866,718
Ensembl chr16:68,860,018...68,866,718
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
increases expression |
EXP |
Paraquat results in increased expression of CHRNA7 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 1:123,897,341...124,039,263
Ensembl chr 1:123,899,657...124,039,196
|
|
G |
Chrnb1 |
cholinergic receptor nicotinic beta 1 subunit |
increases expression |
EXP |
Paraquat results in increased expression of CHRNB1 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr10:56,390,671...56,403,255
Ensembl chr10:56,390,671...56,403,188
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]]; Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein] |
CTD |
PMID:17227438 |
|
NCBI chr 2:189,088,570...189,096,785
Ensembl chr 2:189,088,570...189,096,785
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
increases expression |
EXP |
Paraquat results in increased expression of CHRNE mRNA |
CTD |
PMID:17077588 |
|
NCBI chr10:57,238,960...57,246,750
Ensembl chr10:57,238,946...57,243,435
|
|
G |
Chrng |
cholinergic receptor nicotinic gamma subunit |
affects expression |
EXP |
Paraquat affects the expression of CHRNG mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 9:94,302,218...94,308,591
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein] |
CTD |
PMID:29568078 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
ISO |
Paraquat results in increased expression of CIDEA mRNA |
CTD |
PMID:18836921 |
|
NCBI chr18:63,082,861...63,108,450
Ensembl chr18:63,098,144...63,108,051
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
increases expression |
ISO |
Paraquat results in increased expression of CIDEB mRNA |
CTD |
PMID:18836921 |
|
NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
|
|
G |
Cirbp |
cold inducible RNA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:12,400,066...12,405,054
Ensembl chr 7:12,401,207...12,405,022
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of CLDN1 protein |
CTD |
PMID:30698896 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Clk3 |
CDC-like kinase 3 |
increases expression |
EXP |
Paraquat results in increased expression of CLK3 mRNA |
CTD |
PMID:16328009 |
|
NCBI chr 8:62,528,135...62,543,550
Ensembl chr 8:62,528,225...62,542,622
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
increases expression |
ISO |
Paraquat results in increased expression of CLPX mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 8:70,789,137...70,843,133
Ensembl chr 8:70,789,256...70,843,123
|
|
G |
Clspn |
claspin |
decreases expression |
ISO |
Paraquat results in decreased expression of CLSPN mRNA |
CTD |
PMID:23613995 |
|
NCBI chr 5:144,577,670...144,617,507
Ensembl chr 5:144,581,427...144,616,335
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA |
CTD |
PMID:18386188 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cma1 |
chymase 1 |
multiple interactions increases expression |
ISO EXP |
CMA1 protein promotes the reaction [Paraquat results in increased expression of ACTA2 protein]; CMA1 protein promotes the reaction [Paraquat results in increased expression of AGT protein modified form]; CMA1 protein promotes the reaction [Paraquat results in increased expression of TGFB1 protein] Paraquat results in increased expression of CMA1 mRNA Paraquat results in increased expression of CMA1 mRNA; Paraquat results in increased expression of CMA1 protein |
CTD |
PMID:18198484 PMID:19969051 |
|
NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
increases expression |
EXP |
Paraquat results in increased expression of CMKLR1 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr12:48,743,556...48,796,582
Ensembl chr12:48,789,261...48,793,553
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
increases expression |
ISO |
Paraquat results in increased expression of CMPK2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
decreases expression multiple interactions |
EXP |
Paraquat results in decreased expression of CNR2 protein 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Paraquat results in decreased expression of CNR2 protein] |
CTD |
PMID:24963491 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
EXP ISO |
[Paraquat co-treated with Oxygen] results in increased expression of COL1A1 mRNA; Ambroxol affects the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Anthocyanins inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 protein] Paraquat results in increased expression of COL1A1 mRNA; Paraquat results in increased expression of COL1A1 protein enterotoxin C, staphylococcal analog inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; pirfenidone inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; thymoquinone inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA] Saralasin inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA] |
CTD |
PMID:12882763 PMID:17215068 PMID:19969051 PMID:20035857 PMID:21921364 PMID:24893116 PMID:25304964 PMID:25873302 PMID:26099602 PMID:26221080 PMID:26345256 PMID:27375216 PMID:29273418 PMID:30403199 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Paraquat results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26108578 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions increases expression |
ISO EXP |
ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]]; Saralasin inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA] enterotoxin C, staphylococcal analog inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA] Paraquat results in increased expression of COL3A1 mRNA; Paraquat results in increased expression of COL3A1 protein Ambroxol affects the reaction [Paraquat results in increased expression of COL3A1 mRNA]; Losartan inhibits the reaction [Paraquat results in increased expression of COL3A1 protein] |
CTD |
PMID:20035857 PMID:21921364 PMID:24893116 PMID:25233898 PMID:25304964 PMID:25873302 PMID:25945502 PMID:26099602 PMID:26758514 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions increases expression |
ISO |
pirfenidone inhibits the reaction [Paraquat results in increased expression of COL4A1 mRNA]; thymoquinone inhibits the reaction [Paraquat results in increased expression of COL4A1 mRNA] |
CTD |
PMID:27375216 PMID:29273418 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
ISO |
Paraquat results in increased expression of COL6A1 mRNA |
CTD |
PMID:26345256 |
|
NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
EXP |
Paraquat results in increased expression of COMT mRNA |
CTD |
PMID:17935786 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cope |
COPI coat complex subunit epsilon |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA |
CTD |
PMID:18386188 |
|
NCBI chr16:20,863,141...20,873,516
Ensembl chr16:20,863,141...20,873,521
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
affects expression increases expression decreases expression |
EXP |
Paraquat affects the expression of COX4I1 mRNA Paraquat results in increased expression of COX4I1 protein Paraquat results in decreased expression of COX4I1 mRNA |
CTD |
PMID:15206577 PMID:18198484 PMID:24521700 |
|
NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression multiple interactions |
EXP ISO |
Paraquat results in increased expression of COX5A protein [Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein] |
CTD |
PMID:23562983 PMID:24521700 |
|
NCBI chr 8:62,298,358...62,309,765
Ensembl chr 8:62,298,358...62,309,765
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
decreases expression increases expression |
EXP |
Paraquat results in decreased expression of COX5B mRNA Paraquat results in increased expression of COX5B protein |
CTD |
PMID:17077588 PMID:24521700 |
|
NCBI chr 9:43,259,706...43,262,039
Ensembl chr 9:43,259,709...43,262,040
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr12:47,024,442...47,027,495
Ensembl chr12:47,024,442...47,027,495
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:89,075,987...89,084,834
Ensembl chr 1:89,075,975...89,084,859 Ensembl chr 2:89,075,975...89,084,859
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
increases expression |
EXP |
Paraquat results in increased expression of COX6C protein |
CTD |
PMID:24521700 |
|
NCBI chr 7:74,723,177...74,735,650
Ensembl chr 7:74,723,179...74,735,650
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
decreases expression multiple interactions |
EXP ISO |
Paraquat results in decreased expression of COX7A2 mRNA [Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA |
CTD |
PMID:17077588 PMID:18386188 |
|
NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:6,695,807...6,709,790
Ensembl chr 6:6,695,827...6,709,783
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein |
CTD |
PMID:17532186 |
|
NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Paraquat results in increased expression of CPT1A mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
increases expression |
ISO |
Paraquat results in increased expression of CRADD mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 7:36,395,665...36,408,588
Ensembl chr 7:36,395,665...36,408,588
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Paraquat results in increased phosphorylation of CREB1 protein [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form [Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA] |
CTD |
PMID:16797015 PMID:23963992 PMID:27460631 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Creb3 |
cAMP responsive element binding protein 3 |
increases expression |
ISO |
Paraquat results in increased expression of CREB3 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 5:59,063,532...59,068,196
Ensembl chr 5:59,063,531...59,068,188
|
|
G |
Crebbp |
CREB binding protein |
increases expression decreases expression |
EXP ISO |
Paraquat results in increased expression of CREBBP protein Paraquat results in decreased expression of CREBBP mRNA |
CTD |
PMID:20478973 PMID:28619522 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
ISO |
Paraquat results in increased expression of CRH mRNA; Paraquat results in increased expression of CRH protein |
CTD |
PMID:30744883 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crip2 |
cysteine-rich protein 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
affects expression |
EXP |
Paraquat affects the expression of CRISPLD2 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr19:52,647,038...52,705,118
Ensembl chr19:52,647,070...52,705,131
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of CRLF2 mRNA [Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:1,456,843...1,461,543
Ensembl chr14:1,456,844...1,461,543
|
|
G |
Crot |
carnitine O-octanoyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:22,079,837...22,116,265
Ensembl chr 4:22,081,604...22,116,265
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of CRTC2 mRNA WNT1 protein inhibits the reaction [Paraquat results in decreased expression of CRTC2 mRNA] |
CTD |
PMID:30171970 |
|
NCBI chr 2:189,615,928...189,625,646
Ensembl chr 2:189,615,948...189,626,051
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
affects expression multiple interactions increases expression |
EXP ISO |
Paraquat affects the expression of CSF1R mRNA [Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA] Paraquat results in increased expression of CSF1R mRNA |
CTD |
PMID:15206577 PMID:17077588 PMID:18198484 PMID:21371552 PMID:32169474 |
|
NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Paraquat results in increased expression of CSF2 mRNA |
CTD |
PMID:22938100 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Paraquat results in increased expression of CSF3 protein |
CTD |
PMID:26988026 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Csnk1g2 |
casein kinase 1, gamma 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of CSNK1G2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 7:11,944,957...11,963,268
Ensembl chr 7:11,944,958...11,963,268
|
|
G |
Csnk2a2 |
casein kinase 2 alpha 2 |
increases expression |
ISO |
Paraquat results in increased expression of CSNK2A2 protein |
CTD |
PMID:26649146 |
|
NCBI chr19:9,972,537...10,012,043
Ensembl chr19:9,972,537...10,012,043
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
affects expression |
EXP |
Paraquat affects the expression of CSPG4 mRNA |
CTD |
PMID:16854511 |
|
NCBI chr 8:61,532,465...61,567,510
Ensembl chr 8:61,532,465...61,567,510
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression affects localization decreases expression decreases response to substance |
ISO EXP |
CTNNB1 protein inhibits the reaction [Paraquat results in increased abundance of Reactive Oxygen Species]; Lithium Chloride inhibits the reaction [Paraquat results in decreased expression of CTNNB1 protein]; Paraquat inhibits the reaction [CTNNB1 protein binds to MPZ promoter]; Paraquat inhibits the reaction [CTNNB1 protein binds to PMP22 promoter] Paraquat results in increased expression of CTNNB1 protein Febuxostat inhibits the reaction [Paraquat results in increased expression of CTNNB1 protein] LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein]; Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein; WNT1 protein inhibits the reaction [Paraquat results in decreased expression of CTNNB1 mRNA]; WNT1 protein inhibits the reaction [Paraquat results in decreased expression of CTNNB1 protein] Paraquat results in decreased expression of CTNNB1 mRNA; Paraquat results in decreased expression of CTNNB1 protein CTNNB1 protein results in decreased susceptibility to Paraquat |
CTD |
PMID:23620592 PMID:26887261 PMID:27788593 PMID:30171970 PMID:30205152 PMID:30726711 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
increases expression |
ISO |
Paraquat results in increased expression of CTNNBIP1 mRNA |
CTD |
PMID:28619522 |
|
NCBI chr 5:166,464,170...166,513,030
Ensembl chr 5:166,464,252...166,513,027
|
|
G |
Ctnnd1 |
catenin delta 1 |
multiple interactions decreases expression |
ISO |
mangiferin inhibits the reaction [Paraquat results in decreased expression of and affects the localization of CTNND1 protein]; mangiferin inhibits the reaction [Paraquat results in decreased expression of CTNND1 mRNA alternative form]; Paraquat results in decreased expression of and affects the localization of CTNND1 protein |
CTD |
PMID:24912632 |
|
NCBI chr 3:72,001,904...72,053,047
Ensembl chr 3:72,002,152...72,053,049
|
|
G |
Ctnnd2 |
catenin delta 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of CTNND2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Ctrb1 |
chymotrypsinogen B1 |
increases expression |
EXP |
Paraquat results in increased expression of CTRB mRNA |
CTD |
PMID:18198484 |
|
NCBI chr19:43,906,344...43,911,020
Ensembl chr19:43,906,292...43,911,057
|
|
G |
Ctsb |
cathepsin B |
decreases expression multiple interactions decreases activity |
ISO |
Paraquat results in decreased expression of CTSB mRNA APOD protein inhibits the reaction [Paraquat results in decreased activity of CTSB protein] |
CTD |
PMID:16797015 PMID:28182653 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Paraquat results in decreased expression of CTSC mRNA |
CTD |
PMID:16797015 |
|
NCBI chr 1:151,918,514...151,949,979
Ensembl chr 1:151,918,571...151,949,983
|
|
G |
Ctsd |
cathepsin D |
decreases expression |
ISO |
Paraquat results in decreased expression of CTSD mRNA |
CTD |
PMID:16797015 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsh |
cathepsin H |
decreases expression |
ISO |
Paraquat results in decreased expression of CTSH mRNA |
CTD |
PMID:16797015 |
|
NCBI chr 8:97,439,155...97,458,293
Ensembl chr 8:97,439,161...97,458,287
|
|
G |
Ctsk |
cathepsin K |
increases expression |
ISO |
Paraquat results in increased expression of CTSK mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cul1 |
cullin 1 |
increases expression |
ISO |
Paraquat results in increased expression of CUL1 mRNA |
CTD |
PMID:21371552 PMID:28619522 |
|
NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases response to substance multiple interactions |
ISO |
CX3CR1 protein results in decreased susceptibility to Paraquat [LRRK2 protein results in increased susceptibility to Paraquat] which results in decreased expression of CX3CR1 protein |
CTD |
PMID:23299473 PMID:31174552 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Paraquat results in increased expression of CXCL10 mRNA |
CTD |
PMID:22230393 PMID:26345256 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Paraquat results in increased expression of CXCL11 mRNA |
CTD |
PMID:22230393 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
EXP ISO |
Paraquat results in increased expression of CXCL2 protein Paraquat results in increased expression of CXCL2 mRNA; Paraquat results in increased expression of CXCL2 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Paraquat results in increased expression of CXCL2 protein]; Acetylcysteine inhibits the reaction [Paraquat results in increased expression of CXCL2 protein]; Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]]; SB 203580 inhibits the reaction [Paraquat results in increased expression of CXCL2 protein] [Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CXCL2 protein; SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CXCL2 protein] |
CTD |
PMID:12504350 PMID:16324872 PMID:16919916 PMID:24376630 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression increases expression |
EXP ISO |
Paraquat results in decreased expression of CXCL3 mRNA Paraquat results in increased expression of CXCL1 protein |
CTD |
PMID:18198484 PMID:26988026 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
EXP |
Paraquat results in decreased expression of CXCR4 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyb5a |
cytochrome b5 type A |
increases expression |
ISO |
Paraquat results in increased expression of CYB5A mRNA |
CTD |
PMID:21371552 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:29568078 PMID:30797899 PMID:32375810 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyc1 |
cytochrome c-1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:117,409,576...117,411,953
Ensembl chr 7:117,409,576...117,411,953
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases expression affects localization |
ISO |
[Mifepristone co-treated with NFE2L2 protein] inhibits the reaction [Paraquat results in increased expression of CYCS mRNA]; salubrinal inhibits the reaction [Paraquat affects the localization of CYCS protein] Paraquat results in increased expression of CYCS mRNA; Paraquat results in increased expression of CYCS protein |
CTD |
PMID:20929985 PMID:22736252 PMID:26649146 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cygb |
cytoglobin |
increases expression |
EXP |
Paraquat results in increased expression of CYGB mRNA |
CTD |
PMID:20388547 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression decreases expression |
EXP |
Paraquat results in increased expression of CYP11A1 mRNA Paraquat results in decreased expression of CYP11A1 mRNA; Paraquat results in decreased expression of CYP11A1 protein |
CTD |
PMID:18198484 PMID:31128353 PMID:31610511 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Paraquat results in decreased expression of CYP17A1 mRNA; Paraquat results in decreased expression of CYP17A1 protein |
CTD |
PMID:31128353 PMID:31610511 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Paraquat results in decreased activity of CYP1A1 protein |
CTD |
PMID:17481832 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases activity increases expression multiple interactions |
EXP |
Paraquat results in increased activity of CYP1A2 protein Paraquat results in increased expression of CYP1A2 mRNA; Paraquat results in increased expression of CYP1A2 protein [Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Acetylcysteine inhibits the reaction [Paraquat results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [Paraquat results in increased expression of CYP1A2 mRNA]; Paraquat results in increased expression of and results in increased activity of CYP1A2 protein; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [Paraquat results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [Paraquat results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:20888808 PMID:23159886 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
increases expression |
ISO |
Paraquat results in increased expression of CYP26B1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 4:116,261,796...116,278,615
Ensembl chr 4:116,261,796...116,278,615
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
EXP |
Paraquat results in decreased expression of CYP2C6V1 mRNA |
CTD |
PMID:16328009 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases expression |
ISO |
Ketoconazole inhibits the reaction [Paraquat results in decreased expression of CYP2D22 protein]; resveratrol inhibits the reaction [Paraquat results in decreased expression of CYP2D22 protein] |
CTD |
PMID:22334051 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO EXP |
[Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA] Paraquat results in increased expression of CYP2E1 mRNA; Paraquat results in increased expression of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Paraquat results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Paraquat results in increased expression of CYP2E1 mRNA]; Paraquat promotes the reaction [Zinc Sulfate results in increased expression of CYP2E1 mRNA]; Paraquat results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Paraquat results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Paraquat results in increased expression of CYP2E1 mRNA]; Zinc Sulfate promotes the reaction [Paraquat results in increased expression of CYP2E1 mRNA] Paraquat results in increased activity of CYP2E1 protein |
CTD |
PMID:16510128 PMID:20553223 PMID:20888808 PMID:20964710 PMID:23159886 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
increases expression |
EXP |
Paraquat results in increased expression of CYP2F4 mRNA |
CTD |
PMID:16328009 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
increases expression |
ISO |
Paraquat results in increased expression of CYP2J9 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
EXP |
betanin inhibits the reaction [Paraquat results in increased expression of CYP3A2 mRNA] |
CTD |
PMID:24799198 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
increases expression |
ISO |
Paraquat results in increased expression of CYP46A1 mRNA |
CTD |
PMID:27788593 |
|
NCBI chr 6:132,242,328...132,273,788
Ensembl chr 6:132,242,328...132,273,787
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
Paraquat results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 5:134,468,666...134,484,851
Ensembl chr 5:134,469,270...134,484,839
|
|
G |
Cyth3 |
cytohesin 3 |
increases expression |
ISO |
Paraquat results in increased expression of CYTH3 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr12:12,877,559...12,907,771
Ensembl chr12:12,877,559...12,945,192
|
|
G |
Daam2 |
dishevelled associated activator of morphogenesis 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of DAAM2 mRNA |
CTD |
PMID:28619522 |
|
NCBI chr 9:13,444,883...13,493,154
Ensembl chr 9:13,446,896...13,490,669
|
|
G |
Dap3 |
death associated protein 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression |
ISO |
Paraquat results in increased expression of DAPK1 mRNA |
CTD |
PMID:18836921 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Paraquat results in increased expression of DBP mRNA |
CTD |
PMID:26345256 |
|
NCBI chr 1:101,687,896...101,692,845
Ensembl chr 1:101,687,855...101,692,846
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
increases expression |
EXP |
Paraquat results in increased expression of DDAH1 mRNA |
CTD |
PMID:20388547 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Ddah2 |
dimethylarginine dimethylaminohydrolase 2 |
increases expression |
EXP |
Paraquat results in increased expression of DDAH2 mRNA |
CTD |
PMID:20388547 |
|
NCBI chr20:5,049,260...5,052,573
Ensembl chr20:5,049,496...5,052,585
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
Paraquat results in increased expression of DDB2 mRNA |
CTD |
PMID:23613995 |
|
NCBI chr 3:80,030,437...80,052,984
Ensembl chr 3:80,030,437...80,052,953
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
ISO |
Paraquat results in decreased expression of DDC mRNA |
CTD |
PMID:21371552 |
|
NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Paraquat results in increased expression of DDIT3 mRNA; Paraquat results in increased expression of DDIT3 protein Minocycline inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of DDIT3 mRNA]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of DDIT3 protein] EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein] |
CTD |
PMID:19735704 PMID:20883675 PMID:22245251 PMID:22678742 PMID:23613995 PMID:27442881 PMID:28986289 PMID:30185695 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Paraquat results in increased expression of DDIT4 mRNA |
CTD |
PMID:23613995 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions decreases expression |
ISO |
6-bromoindirubin-3'-oxime promotes the reaction [Paraquat inhibits the reaction [TNFRSF10B protein binds to DDX3X protein]]; 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in decreased expression of DDX3X protein modified form]; Paraquat inhibits the reaction [TNFRSF10B protein binds to DDX3X protein] |
CTD |
PMID:28414160 |
|
NCBI chr X:10,400,363...10,414,010
Ensembl chr X:10,400,366...10,413,995
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:94,979,759...94,988,461
Ensembl chr10:94,980,928...94,988,461
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
increases expression |
ISO |
Paraquat results in increased expression of DFFA mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 5:165,922,893...165,935,822
Ensembl chr 5:165,922,915...165,935,821
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
decreases expression |
ISO |
Paraquat results in decreased expression of DGKB mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 6:57,516,351...58,277,385
Ensembl chr 6:57,516,713...58,277,279
|
|
G |
Dgkh |
diacylglycerol kinase, eta |
increases expression |
ISO |
Paraquat results in increased expression of DGKH mRNA |
CTD |
PMID:22563483 |
|
NCBI chr15:60,791,574...60,967,236
Ensembl chr15:60,803,098...60,959,769
|
|
G |
Dgki |
diacylglycerol kinase, iota |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of DGKI mRNA [Paraquat co-treated with Maneb] affects the expression of DGKI mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
Paraquat results in decreased expression of DHCR24 mRNA |
CTD |
PMID:23315990 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
EXP |
Paraquat results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16328009 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Dhh |
desert hedgehog signaling molecule |
affects expression decreases expression increases expression |
EXP |
Paraquat affects the expression of DHH protein Paraquat results in decreased expression of DHH mRNA Paraquat results in increased expression of DHH protein |
CTD |
PMID:31128353 |
|
NCBI chr 7:140,575,288...140,580,783
Ensembl chr 7:140,575,288...140,580,783
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions increases transport affects localization increases expression |
EXP ISO |
Cyclosporine inhibits the reaction [Paraquat affects the localization of DIABLO protein]; Dibucaine inhibits the reaction [Paraquat affects the localization of DIABLO protein]; diphenyleneiodonium inhibits the reaction [Paraquat affects the localization of DIABLO protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of DIABLO protein] Paraquat results in increased transport of DIABLO protein LGK974 inhibits the reaction [Paraquat results in increased transport of DIABLO protein] |
CTD |
PMID:17936647 PMID:22245251 PMID:25947082 PMID:30205152 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dip2b |
disco-interacting protein 2 homolog B |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA Paraquat results in increased expression of DIP2B mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:141,702,034...141,878,945
Ensembl chr 7:141,702,038...141,879,951
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
ISO |
Paraquat results in decreased expression of DLD mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions decreases expression |
EXP |
Estradiol inhibits the reaction [Paraquat results in decreased expression of DLG4 protein] |
CTD |
PMID:31715309 |
|
NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein] |
CTD |
PMID:23562983 |
|
NCBI chr 6:108,936,534...108,961,322
Ensembl chr 6:108,936,664...108,959,803
|
|
G |
Dmd |
dystrophin |
increases response to substance |
ISO |
DMD gene mutant form results in increased susceptibility to Paraquat |
CTD |
PMID:10797403 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Dmrta2 |
DMRT-like family A2 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of DMRTA2 mRNA [Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:129,754,295...129,760,045
Ensembl chr 5:129,756,149...129,758,986
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases response to substance |
ISO |
DNAJB1 protein results in decreased susceptibility to Paraquat |
CTD |
PMID:11359866 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Paraquat results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:16797015 |
|
NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression |
ISO |
Paraquat results in increased expression of DNM1L protein |
CTD |
PMID:28215578 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of DNMT1 mRNA; Paraquat results in decreased expression of DNMT1 protein |
CTD |
PMID:31189234 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
decreases expression |
ISO |
Paraquat results in decreased expression of DNMT3A mRNA; Paraquat results in decreased expression of DNMT3A protein |
CTD |
PMID:31189234 |
|
NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
increases expression |
ISO |
Paraquat results in increased expression of DNMT3B |
CTD |
PMID:31189234 |
|
NCBI chr 3:149,131,541...149,170,061
Ensembl chr 3:149,131,785...149,208,786
|
|
G |
Dok4 |
docking protein 4 |
increases expression |
ISO |
Paraquat results in increased expression of DOK4 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr19:10,563,423...10,574,094
Ensembl chr19:10,563,423...10,574,093
|
|
G |
Drd2 |
dopamine receptor D2 |
affects expression increases expression multiple interactions |
EXP ISO |
Paraquat affects the expression of DRD2 mRNA Paraquat results in increased expression of DRD2 mRNA [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA |
CTD |
PMID:15206577 PMID:18198484 PMID:23017109 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Drd4 |
dopamine receptor D4 |
affects expression multiple interactions |
EXP ISO |
Paraquat affects the expression of DRD4 mRNA [Paraquat co-treated with Maneb] results in increased expression of DRD4 protein |
CTD |
PMID:15206577 PMID:22563483 |
|
NCBI chr 1:214,278,296...214,282,818
Ensembl chr 1:214,278,296...214,281,483
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr14:77,220,579...77,222,006
Ensembl chr14:77,220,579...77,222,006
|
|
G |
Dtx1 |
deltex E3 ubiquitin ligase 1 |
affects expression |
ISO |
Paraquat affects the expression of DTX1 mRNA |
CTD |
PMID:24053911 |
|
NCBI chr12:41,383,885...41,415,783
Ensembl chr12:41,385,241...41,414,754
|
|
G |
Duox1 |
dual oxidase 1 |
multiple interactions increases expression |
ISO |
APOD protein affects the reaction [Paraquat results in increased expression of DUOX1 mRNA] kaempferol inhibits the reaction [Paraquat results in increased expression of DUOX1 mRNA] |
CTD |
PMID:21688324 PMID:25177032 |
|
NCBI chr 3:114,251,794...114,286,827
Ensembl chr 3:114,253,637...114,286,802
|
|
G |
Duox2 |
dual oxidase 2 |
multiple interactions |
ISO |
[Quercetin co-treated with Paraquat] results in increased expression of DUOX2 mRNA |
CTD |
PMID:22996356 |
|
NCBI chr 3:114,218,187...114,237,808
Ensembl chr 3:114,218,193...114,235,933
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Paraquat results in increased expression of DUSP1 mRNA |
CTD |
PMID:12595580 PMID:23315990 PMID:28012437 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
decreases expression multiple interactions |
EXP ISO |
Paraquat results in decreased expression of DVL2 mRNA Lithium Chloride inhibits the reaction [Paraquat results in decreased expression of DVL2 protein] WNT1 protein inhibits the reaction [Paraquat results in decreased expression of DVL2 mRNA]; WNT1 protein inhibits the reaction [Paraquat results in decreased expression of DVL2 protein] Paraquat results in decreased expression of DVL2 mRNA; Paraquat results in decreased expression of DVL2 protein |
CTD |
PMID:26887261 PMID:27788593 PMID:30171970 |
|
NCBI chr10:56,609,810...56,619,269
Ensembl chr10:56,610,051...56,619,269
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
decreases expression increases expression |
ISO EXP |
Paraquat results in decreased expression of DYNLL1 mRNA Paraquat results in increased expression of DYNLL1 mRNA |
CTD |
PMID:12595580 PMID:16328009 PMID:20388547 |
|
NCBI chr12:47,074,200...47,076,573
Ensembl chr12:47,074,200...47,076,572
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
increases expression |
ISO |
Paraquat results in increased expression of DYRK1A mRNA |
CTD |
PMID:21371552 |
|
NCBI chr11:34,858,339...34,958,733
Ensembl chr11:34,865,532...34,956,536
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
multiple interactions increases expression |
ISO |
salubrinal inhibits the reaction [Paraquat results in increased expression of EDEM1 protein] |
CTD |
PMID:19735704 |
|
NCBI chr 4:140,886,644...140,918,654
Ensembl chr 4:140,886,545...140,915,779
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases expression |
EXP ISO |
green tea extract AR25 inhibits the reaction [Paraquat results in increased expression of EDN1 mRNA]; green tea extract AR25 inhibits the reaction [Paraquat results in increased expression of EDN1 protein] Acetylcysteine inhibits the reaction [Paraquat results in increased expression of EDN1 mRNA]; Dapsone inhibits the reaction [Paraquat results in increased expression of EDN1 mRNA] Paraquat results in increased expression of EDN1 mRNA; Paraquat results in increased expression of EDN1 protein |
CTD |
PMID:17235729 PMID:21765237 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednra |
endothelin receptor type A |
affects expression |
EXP |
Paraquat affects the expression of EDNRA mRNA |
CTD |
PMID:16854511 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of EEF1A2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 3:176,657,104...176,666,282
Ensembl chr 3:176,657,107...176,666,282
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:225,163,391...225,173,997
Ensembl chr 1:225,163,391...225,173,995
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
decreases expression |
ISO |
Paraquat results in decreased expression of EEF2K mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 1:190,780,211...190,839,926
Ensembl chr 1:190,780,236...190,842,324
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr X:68,891,227...68,904,034
Ensembl chr X:68,891,227...68,904,038
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of EGFR protein |
CTD |
PMID:17298174 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egln2 |
egl-9 family hypoxia-inducible factor 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of EGLN2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:83,969,456...83,977,665
Ensembl chr 1:83,969,457...83,977,236
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Paraquat results in increased expression of EGR1 mRNA |
CTD |
PMID:20883675 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions decreases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA Paraquat results in decreased expression of EGR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation |
ISO |
Paraquat results in increased phosphorylation of EIF2A protein |
CTD |
PMID:20929985 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation increases expression |
EXP ISO |
Paraquat results in increased phosphorylation of EIF2AK3 protein Paraquat results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:22245251 PMID:27442881 PMID:28986289 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions increases expression |
EXP ISO |
Paraquat results in increased phosphorylation of EIF2S1 protein EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal promotes the reaction [Paraquat results in increased expression of EIF2S1 protein modified form] |
CTD |
PMID:22245251 PMID:27442881 PMID:28986289 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
Paraquat results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:175,883,362...175,895,510
Ensembl chr 1:175,883,363...175,895,510
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
affects localization |
ISO |
Paraquat affects the localization of ELAVL1 protein |
CTD |
PMID:22879928 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Eln |
elastin |
increases expression |
ISO |
Paraquat results in increased expression of ELN mRNA |
CTD |
PMID:17215068 PMID:26345256 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
increases expression |
ISO |
Paraquat results in increased expression of ELP1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 5:73,503,406...73,552,798
Ensembl chr 5:73,503,407...73,552,798
|
|
G |
Eno1 |
enolase 1 |
multiple interactions decreases expression |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein] Paraquat results in decreased expression of ENO1 mRNA; Paraquat results in decreased expression of ENO1 protein |
CTD |
PMID:17532186 PMID:18386188 PMID:23562983 PMID:27111068 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Eno2 |
enolase 2 |
increases expression multiple interactions decreases expression |
ISO EXP |
Paraquat results in increased expression of ENO2 mRNA alternative form [Maneb co-treated with Paraquat] results in increased expression of ENO2 protein Paraquat results in decreased expression of ENO2 protein |
CTD |
PMID:17064354 PMID:18198484 PMID:23562983 PMID:24521700 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Epn2 |
epsin 2 |
increases expression |
ISO |
Paraquat results in increased expression of EPN2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr10:47,795,496...47,857,373
Ensembl chr10:47,795,524...47,857,326
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [SOD2 gene mutant form results in increased susceptibility to Paraquat] |
CTD |
PMID:16288465 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
decreases expression |
ISO |
Paraquat results in decreased expression of EPS8 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 4:171,475,155...171,645,620
Ensembl chr 4:171,475,567...171,591,882
|
|
G |
Epx |
eosinophil peroxidase |
multiple interactions decreases expression |
ISO |
APOD protein affects the reaction [Paraquat results in decreased expression of EPX mRNA] |
CTD |
PMID:21688324 |
|
NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases response to substance |
ISO |
NFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Paraquat] |
CTD |
PMID:25467193 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Paraquat results in decreased expression of ERBB3 mRNA |
CTD |
PMID:16797015 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression |
ISO |
Paraquat results in increased expression of ERBB4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
affects splicing |
ISO |
Paraquat affects the splicing of ERCC1 mRNA |
CTD |
PMID:23613995 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases response to substance |
ISO |
ERCC6 gene mutant form results in increased susceptibility to Paraquat |
CTD |
PMID:12509265 PMID:15340056 |
|
NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
|
|
G |
Ergic2 |
ERGIC and golgi 2 |
decreases expression increases expression |
ISO |
Paraquat results in decreased expression of ERGIC2 mRNA Paraquat results in increased expression of ERGIC2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 4:182,569,086...182,600,258
Ensembl chr 4:182,569,089...182,600,258
|
|
G |
Ermp1 |
endoplasmic reticulum metallopeptidase 1 |
increases expression |
ISO |
Paraquat results in increased expression of ERMP1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:247,784,830...247,821,771
Ensembl chr 1:247,787,582...247,821,728
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
Paraquat promotes the reaction [MAP3K5 protein results in increased phosphorylation of ERN1 protein] Paraquat results in increased expression of ERN1 protein modified form Paraquat results in increased phosphorylation of ERN1 protein |
CTD |
PMID:20929985 PMID:22245251 PMID:28986289 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases activity |
EXP |
Paraquat results in decreased activity of ESR1 protein |
CTD |
PMID:31715309 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Paraquat results in decreased expression of ESRRA mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Etl4 |
enhancer trap locus 4 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of ETL4 mRNA [Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:87,173,265...87,681,268
Ensembl chr17:87,274,944...87,681,317
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
decreases expression |
EXP |
Paraquat results in decreased expression of ETS1 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
F2 |
coagulation factor II |
increases expression |
EXP |
Paraquat results in increased expression of F2 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Faah |
fatty acid amide hydrolase |
increases expression |
EXP |
Paraquat results in increased expression of FAAH mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
ISO |
Paraquat results in increased expression of FABP5 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression |
ISO |
Paraquat results in decreased expression of FADD mRNA |
CTD |
PMID:18836921 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of FADS2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fanca |
FA complementation group A |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCA mRNA |
CTD |
PMID:28012437 |
|
NCBI chr19:56,067,548...56,126,075
Ensembl chr19:56,067,548...56,126,063
|
|
G |
Fancb |
FA complementation group B |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCB mRNA |
CTD |
PMID:28012437 |
|
NCBI chr X:31,124,018...31,140,790
Ensembl chr X:31,124,018...31,140,711
|
|
G |
Fancd2 |
FA complementation group D2 |
multiple interactions |
ISO |
[ATG7 protein affects the susceptibility to Paraquat] which affects the expression of FANCD2 mRNA |
CTD |
PMID:28012437 |
|
NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of FAS mRNA [Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA] |
CTD |
PMID:18836921 PMID:23963992 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Paraquat results in increased expression of FASL mRNA Paraquat results in increased expression of FASLG mRNA |
CTD |
PMID:9657385 PMID:17215068 PMID:18836921 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
increases expression |
ISO |
Paraquat results in increased expression of FAT3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
Paraquat results in increased expression of FGF1 mRNA |
CTD |
PMID:16324872 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression decreases secretion multiple interactions |
EXP ISO |
Paraquat results in increased expression of FGF2 mRNA Paraquat results in decreased secretion of FGF2 protein Oxygen inhibits the reaction [Paraquat results in increased expression of FGF2 mRNA] |
CTD |
PMID:18198484 PMID:26722498 PMID:30698896 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
multiple interactions affects response to substance |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA FKBP4 protein affects the susceptibility to Paraquat |
CTD |
PMID:18386188 PMID:20713718 |
|
NCBI chr 4:161,748,993...161,757,447
Ensembl chr 4:161,748,993...161,757,447
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression multiple interactions affects expression |
ISO EXP |
Paraquat results in increased expression of FKBP5 mRNA [Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA Paraquat affects the expression of FKBP5 mRNA |
CTD |
PMID:12595580 PMID:16854511 PMID:18386188 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression multiple interactions increases expression |
ISO EXP |
Paraquat results in decreased expression of FN1 mRNA THBS1 protein affects the reaction [Paraquat results in increased expression of FN1 protein] Paraquat results in increased expression of FN1 mRNA; Paraquat results in increased expression of FN1 protein prolinedithiocarbamate inhibits the reaction [Paraquat results in increased expression of FN1 mRNA] |
CTD |
PMID:16797015 PMID:17215068 PMID:23803522 PMID:25873302 PMID:26345256 PMID:29495171 PMID:30317802 PMID:30419666 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Paraquat promotes the reaction [JUN protein binds to FOS protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA] Paraquat results in increased expression of FOS mRNA [Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein [Paraquat co-treated with SOD2 protein] results in increased expression of FOS mRNA |
CTD |
PMID:10464329 PMID:11728812 PMID:17048122 PMID:23963992 PMID:27460631 PMID:29441825 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxm1 |
forkhead box M1 |
decreases expression |
ISO |
Paraquat results in decreased expression of FOXM1 mRNA |
CTD |
PMID:23315990 |
|
NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions affects expression increases response to substance |
ISO |
FOXO3 mutant form inhibits the reaction [Paraquat results in increased expression of BCL2L11 mRNA] Paraquat affects the expression of FOXO3 mRNA FOXO3 protein results in increased susceptibility to Paraquat |
CTD |
PMID:23620592 PMID:29287252 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Fstl1 |
follistatin-like 1 |
multiple interactions increases expression |
ISO |
plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of FSTL1 mRNA]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in increased expression of FSTL1 protein] Paraquat results in increased expression of FSTL1 mRNA; Paraquat results in increased expression of FSTL1 protein |
CTD |
PMID:26758514 |
|
NCBI chr11:65,791,196...65,845,721
Ensembl chr11:65,782,567...65,845,418
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO |
Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] Paraquat results in increased expression of FTL1 mRNA; Paraquat results in increased expression of FTL1 protein |
CTD |
PMID:12644586 PMID:28542246 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Ftmt |
ferritin mitochondrial |
multiple interactions |
ISO |
Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] |
CTD |
PMID:12644586 |
|
NCBI chr18:47,294,292...47,295,541
Ensembl chr18:47,294,292...47,295,541
|
|
G |
Fut2 |
fucosyltransferase 2 |
increases expression |
EXP |
Paraquat results in increased expression of FUT2 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 1:101,631,633...101,651,668
Ensembl chr 1:101,631,635...101,651,668
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:49,676,520...49,703,419
Ensembl chr 8:49,676,540...49,703,419
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions affects expression increases activity |
EXP |
FYN protein affects the reaction [Paraquat results in decreased expression of PDGFRA protein] Paraquat affects the expression of FYN mRNA Paraquat results in increased activity of FYN protein |
CTD |
PMID:15206577 PMID:17298174 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression multiple interactions |
EXP ISO |
Paraquat results in decreased expression of FZD1 mRNA Paraquat results in decreased expression of FZD1 mRNA; Paraquat results in decreased expression of FZD1 protein WNT1 protein inhibits the reaction [Paraquat results in decreased expression of FZD1 mRNA] |
CTD |
PMID:26887261 PMID:30171970 |
|
NCBI chr 4:26,470,864...26,475,262
Ensembl chr 4:26,470,864...26,475,262
|
|
G |
Fzd4 |
frizzled class receptor 4 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of FZD4 mRNA WNT1 protein inhibits the reaction [Paraquat results in decreased expression of FZD4 mRNA] Paraquat results in decreased expression of FZD4 mRNA; Paraquat results in decreased expression of FZD4 protein |
CTD |
PMID:28619522 PMID:30171970 |
|
NCBI chr 1:153,589,471...153,598,376
Ensembl chr 1:153,589,471...153,598,375
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
Paraquat results in increased activity of G6PDX protein |
CTD |
PMID:10699569 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gab1 |
GRB2-associated binding protein 1 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of GAB1 mRNA APOD protein affects the reaction [Paraquat results in decreased expression of GAB1 mRNA] |
CTD |
PMID:21688324 |
|
NCBI chr19:30,794,290...30,903,819
Ensembl chr19:30,794,571...30,902,008
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
Paraquat results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
decreases expression |
ISO EXP |
Paraquat results in decreased expression of GABBR1 mRNA Paraquat results in decreased expression of GABBR1 protein |
CTD |
PMID:21371552 PMID:24521700 |
|
NCBI chr20:1,955,344...1,984,907
Ensembl chr20:1,955,359...1,984,863
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
EXP |
Paraquat results in increased expression of GABRA4 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:27,847,447...27,862,896
Ensembl chr10:27,847,439...27,862,868
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
decreases expression |
EXP |
Paraquat results in decreased expression of GABRB1 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr14:38,631,192...39,112,598
Ensembl chr14:38,643,385...39,112,600
|
|
G |
Gabrd |
gamma-aminobutyric acid type A receptor subunit delta |
decreases expression |
EXP |
Paraquat results in decreased expression of GABRD mRNA |
CTD |
PMID:19146868 |
|
NCBI chr 5:172,797,478...172,809,374
Ensembl chr 5:172,797,450...172,809,353
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression |
EXP |
Paraquat results in decreased expression of GAD1 mRNA |
CTD |
PMID:17493592 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression |
EXP |
Paraquat results in decreased expression of GAD2 mRNA; Paraquat results in decreased expression of GAD2 protein |
CTD |
PMID:18198484 PMID:24521700 |
|
NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO EXP |
GPX1 protein affects the reaction [Paraquat affects the expression of GADD45A mRNA] Paraquat results in increased expression of GADD45A mRNA |
CTD |
PMID:12595580 PMID:12654481 PMID:15246999 PMID:17935786 PMID:18836921 PMID:19526292 PMID:20883675 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Paraquat results in increased expression of GADD45B mRNA |
CTD |
PMID:12595580 PMID:15246999 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Paraquat results in increased expression of GADD45G mRNA |
CTD |
PMID:12595580 PMID:15246999 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Gak |
cyclin G associated kinase |
increases expression |
EXP |
Paraquat results in increased expression of GAK mRNA |
CTD |
PMID:18198484 |
|
NCBI chr14:2,100,104...2,174,332
Ensembl chr14:2,100,106...2,174,318
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Paraquat results in increased expression of GAP43 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions affects localization |
EXP |
[7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat affects the localization of GAPDH protein]; Selegiline inhibits the reaction [Paraquat affects the localization of GAPDH protein] |
CTD |
PMID:20478973 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gart |
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase |
increases expression decreases expression |
ISO |
Paraquat results in increased expression of GART mRNA Paraquat results in decreased expression of GART mRNA |
CTD |
PMID:21371552 |
|
NCBI chr11:31,780,477...31,805,728
Ensembl chr11:31,780,487...31,805,728
|
|
G |
Gas5 |
growth arrest specific 5 |
multiple interactions decreases expression |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA Paraquat results in decreased expression of GAS5 mRNA |
CTD |
PMID:18386188 PMID:26824344 |
|
NCBI chr13:78,852,523...78,855,844
|
|
G |
Gast |
gastrin |
increases expression |
EXP |
Paraquat results in increased expression of GAST mRNA |
CTD |
PMID:18198484 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression |
ISO |
Paraquat results in decreased expression of GATA3 |
CTD |
PMID:25496228 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gcgr |
glucagon receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of GCGR mRNA |
CTD |
PMID:17077588 |
|
NCBI chr10:109,707,863...109,716,253
Ensembl chr10:109,707,962...109,716,128
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
EXP |
Paraquat results in increased expression of GCH1 mRNA |
CTD |
PMID:20388547 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions decreases expression affects expression |
ISO EXP |
Paraquat results in increased expression of GCLC mRNA SIRT6 promotes the reaction [Paraquat results in increased expression of GCLC mRNA] Paraquat results in decreased expression of GCLC mRNA; Paraquat results in decreased expression of GCLC protein [alpha-Tocopherol co-treated with Paraquat] results in increased expression of GCLC mRNA; Acetylcysteine inhibits the reaction [Paraquat results in decreased expression of GCLC protein]; CAT protein inhibits the reaction [Paraquat results in decreased expression of GCLC protein]; meloxicam inhibits the reaction [Paraquat results in decreased expression of GCLC protein] Paraquat affects the expression of GCLC mRNA |
CTD |
PMID:16854511 PMID:17215068 PMID:20851755 PMID:24530478 PMID:24866057 PMID:26598004 PMID:28467894 PMID:31216030 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases response to substance increases expression decreases expression multiple interactions |
ISO EXP |
GCLM gene mutant form results in increased susceptibility to Paraquat Paraquat results in increased expression of GCLM mRNA Paraquat results in decreased expression of GCLM protein [alpha-Tocopherol co-treated with Paraquat] results in increased expression of GCLM mRNA [GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine; [GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased activity of ACO2 protein; SIRT6 promotes the reaction [Paraquat results in increased expression of GCLM mRNA] |
CTD |
PMID:23704229 PMID:24530478 PMID:27993944 PMID:28467894 PMID:31216030 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Paraquat results in increased expression of GDF15 mRNA |
CTD |
PMID:20883675 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gdf3 |
growth differentiation factor 3 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of GDF3 mRNA; Paraquat results in increased expression of GDF3 protein Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein] |
CTD |
PMID:30698896 PMID:31400064 |
|
NCBI chr 4:155,417,667...155,422,014
Ensembl chr 4:155,417,004...155,421,998
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases response to substance increases expression multiple interactions |
ISO |
GDNF protein results in decreased susceptibility to Paraquat Paraquat results in increased expression of GDNF mRNA APOD protein affects the reaction [Paraquat results in increased expression of GDNF mRNA] |
CTD |
PMID:17935603 PMID:21688324 PMID:29454966 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions affects expression increases expression |
ISO EXP |
[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein]; APOD protein affects the reaction [Paraquat results in increased expression of GFAP protein] Paraquat affects the expression of GFAP mRNA Paraquat results in increased expression of GFAP mRNA; Paraquat results in increased expression of GFAP protein [Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of GFAP protein |
CTD |
PMID:21688324 PMID:24376630 PMID:24521700 PMID:25314302 PMID:28467894 PMID:29454966 PMID:30280190 PMID:30698896 PMID:30797899 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
increases expression |
EXP |
Paraquat results in increased expression of GFRA1 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
increases expression |
EXP |
Paraquat results in increased expression of GFRA2 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr15:52,557,004...52,648,984
Ensembl chr15:52,557,607...52,648,972
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GH mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Ghr |
growth hormone receptor |
increases response to substance affects response to substance decreases response to substance |
ISO |
GHR gene mutant form results in increased susceptibility to Paraquat GHR protein affects the susceptibility to Paraquat GHR gene mutant form results in decreased susceptibility to Paraquat |
CTD |
PMID:12384824 PMID:15701676 PMID:16713617 PMID:19786089 |
|
NCBI chr 2:53,149,225...53,413,954
Ensembl chr 2:53,150,370...53,413,638
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
GHRL protein inhibits the reaction [Paraquat results in increased activity of CASP3 protein] |
CTD |
PMID:31381934 |
|
NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
|
|
G |
Ghsr |
growth hormone secretagogue receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of GHSR mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 2:113,065,953...113,071,265
Ensembl chr 2:113,066,885...113,070,261
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of GJA1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of GJB1 mRNA |
CTD |
PMID:16797015 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Glrx |
glutaredoxin |
increases response to substance increases expression |
ISO |
GLRX gene mutant form results in increased susceptibility to Paraquat Paraquat results in increased expression of GLRX mRNA |
CTD |
PMID:12732627 PMID:17893043 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Glrx2 |
glutaredoxin 2 |
decreases expression increases expression |
ISO |
Paraquat results in decreased expression of GLRX2 mRNA Paraquat results in increased expression of GLRX2 mRNA |
CTD |
PMID:12732627 PMID:21371552 |
|
NCBI chr13:60,529,057...60,552,115
Ensembl chr13:60,529,932...60,537,916
|
|
G |
Gls |
glutaminase |
decreases activity |
EXP |
Paraquat results in decreased activity of GLS protein |
CTD |
PMID:28916328 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions affects expression decreases expression increases expression |
EXP ISO |
[Paraquat results in increased abundance of Reactive Oxygen Species] which results in decreased expression of GLUL protein; SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in decreased expression of GLUL protein] Paraquat affects the expression of GLUL mRNA Paraquat results in decreased expression of GLUL protein Paraquat results in increased expression of GLUL protein |
CTD |
PMID:24376630 PMID:24521700 PMID:29454966 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Gm2a |
GM2 ganglioside activator |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:40,438,394...40,450,927
Ensembl chr10:40,438,356...40,450,930
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein |
CTD |
PMID:17532186 |
|
NCBI chr15:23,597,846...23,611,541
Ensembl chr15:23,601,368...23,606,634
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
EXP |
Paraquat results in increased expression of GNAI3 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
affects expression |
EXP |
Paraquat affects the expression of GNAO1 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr19:11,513,201...11,669,578
Ensembl chr19:11,513,201...11,669,578
|
|
G |
Gnas |
GNAS complex locus |
increases expression affects expression |
ISO EXP |
Paraquat results in increased expression of GNAS mRNA Paraquat affects the expression of GNAS mRNA |
CTD |
PMID:15206577 PMID:16797015 |
|
NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483 Ensembl chr 3:172,374,957...172,428,483
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:252,359,976...252,368,473
Ensembl chr 2:252,359,976...252,368,473
|
|
G |
Gngt2 |
G protein subunit gamma transducin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:83,654,321...83,658,601
Ensembl chr10:83,655,460...83,658,589
|
|
G |
Gnrhr |
gonadotropin releasing hormone receptor |
decreases expression |
EXP |
Paraquat results in decreased expression of GNRHR mRNA |
CTD |
PMID:17077588 |
|
NCBI chr14:23,480,462...23,498,450
Ensembl chr14:23,480,462...23,498,450
|
|
G |
Gopc |
golgi associated PDZ and coiled-coil motif containing |
increases expression |
ISO |
Paraquat results in increased expression of GOPC mRNA |
CTD |
PMID:21371552 |
|
NCBI chr20:33,471,355...33,521,281
Ensembl chr20:33,471,351...33,521,311
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases activity increases expression |
EXP |
Paraquat results in decreased activity of GOT1 protein Paraquat results in increased expression of GOT1 mRNA |
CTD |
PMID:16555045 PMID:17481832 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of GOT2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr19:9,587,637...9,613,323
Ensembl chr19:9,587,653...9,613,340
|
|
G |
Gpc1 |
glypican 1 |
affects expression |
EXP |
Paraquat affects the expression of GPC1 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr 9:99,998,275...100,026,818
Ensembl chr 9:99,998,275...100,026,818
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
increases expression |
EXP |
Paraquat results in increased expression of GPER1 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of GPR27 mRNA [Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926
|
|
G |
Gpr6 |
G protein-coupled receptor 6 |
increases expression |
EXP |
Paraquat results in increased expression of GPR6 mRNA |
CTD |
PMID:17077588 |
|
NCBI chr20:45,813,169...45,815,940
Ensembl chr20:45,813,169...45,815,940
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
ISO |
NME1 protein affects the reaction [Paraquat results in increased activity of GPT protein] |
CTD |
PMID:28077425 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression affects expression decreases expression multiple interactions decreases response to substance increases response to substance |
ISO EXP |
Paraquat results in increased expression of GPX1 mRNA Paraquat affects the expression of GPX1 protein Paraquat results in decreased expression of GPX1 mRNA [Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA; [Paraquat results in increased abundance of Reactive Oxygen Species] which results in decreased expression of GPX1 mRNA; Estradiol affects the reaction [Paraquat affects the expression of GPX1 protein] GPX1 protein results in decreased susceptibility to Paraquat GPX1 protein affects the reaction [Paraquat affects the expression of BAX mRNA]; GPX1 protein affects the reaction [Paraquat affects the expression of BCL2 mRNA]; GPX1 protein affects the reaction [Paraquat affects the expression of BCL2L2 mRNA]; GPX1 protein affects the reaction [Paraquat affects the expression of GADD45A mRNA]; GPX1 protein affects the reaction [Paraquat affects the expression of MDM2 mRNA]; GPX1 protein affects the reaction [Paraquat affects the expression of MYC mRNA]; GPX1 protein affects the reaction [Paraquat results in increased activity of CASP3 protein]; GPX1 protein affects the reaction [Paraquat results in increased expression of BCL2L1 protein]; GPX1 protein affects the reaction [Paraquat results in increased expression of CASP3 protein]; pirfenidone inhibits the reaction [Paraquat results in decreased expression of GPX1 mRNA]; resolvin D1 analog inhibits the reaction [Paraquat results in decreased expression of GPX1 mRNA]; Sodium Selenite affects the reaction [GPX1 gene mutant form affects the susceptibility to Paraquat] [Plant Extracts co-treated with Paraquat] results in increased expression of GPX1 mRNA; GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb]; Plant Extracts inhibits the reaction [Paraquat results in decreased expression of GPX1 mRNA] GPX1 gene mutant form results in increased susceptibility to Paraquat |
CTD |
PMID:11568445 PMID:12595580 PMID:12654481 PMID:15182862 PMID:15824117 PMID:17935786 PMID:18686095 PMID:21371552 PMID:24141985 PMID:24376630 PMID:26108578 PMID:29273418 PMID:29287252 PMID:29859004 PMID:30243747 PMID:30562684 PMID:31715309 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression multiple interactions decreases expression affects expression |
ISO |
Paraquat results in increased expression of GPX2 mRNA [Paraquat co-treated with naringenin] results in increased expression of GPX2 mRNA Paraquat results in decreased expression of GPX2 mRNA APOD protein affects the reaction [Paraquat results in decreased expression of GPX2 mRNA] Paraquat affects the expression of GPX2 mRNA |
CTD |
PMID:10806356 PMID:12732627 PMID:21688324 PMID:24561720 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
affects expression multiple interactions decreases expression increases expression |
EXP ISO |
Paraquat affects the expression of GPX3 mRNA [Paraquat co-treated with naringenin] results in increased expression of GPX3 mRNA; [Paraquat co-treated with Thioctic Acid] results in increased expression of GPX3 mRNA Paraquat results in decreased expression of GPX3 mRNA Paraquat results in increased expression of GPX3 mRNA APOD protein affects the reaction [Paraquat results in increased expression of GPX3 mRNA] |
CTD |
PMID:12732627 PMID:15206577 PMID:18198484 PMID:21688324 PMID:23649336 PMID:24561720 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases response to substance multiple interactions increases expression decreases response to substance |
ISO |
GPX4 gene mutant form results in increased susceptibility to Paraquat [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein] Paraquat results in increased expression of GPX4 mRNA GPX4 protein results in decreased susceptibility to Paraquat |
CTD |
PMID:12566075 PMID:12732627 PMID:30797899 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gpx5 |
glutathione peroxidase 5 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of GPX5 mRNA [Paraquat co-treated with naringenin] results in increased expression of GPX5 mRNA; [Quercetin co-treated with Paraquat] results in increased expression of GPX5 mRNA |
CTD |
PMID:22996356 PMID:24561720 |
|
NCBI chr17:45,508,657...45,518,686
Ensembl chr17:45,467,015...45,518,686
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX7 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 5:128,001,766...128,009,610
Ensembl chr 5:128,001,761...128,009,735
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
decreases expression |
EXP |
Paraquat results in decreased expression of GRIA2 protein |
CTD |
PMID:24521700 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression |
EXP |
Paraquat results in decreased expression of GRIK3 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression multiple interactions |
EXP |
Paraquat results in decreased expression of GRIN1 mRNA; Paraquat results in decreased expression of NMDAR1 protein Estradiol inhibits the reaction [Paraquat results in decreased expression of NMDAR1 protein] |
CTD |
PMID:19146868 PMID:28916328 PMID:31715309 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases expression |
ISO EXP |
Paraquat results in increased expression of GRIN2A mRNA |
CTD |
PMID:18198484 PMID:22563483 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
increases expression affects expression |
ISO EXP |
Paraquat results in increased expression of GRIN2B mRNA Paraquat affects the expression of GRIN2B mRNA |
CTD |
PMID:15206577 PMID:22563483 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Paraquat results in increased expression of GRIN2C mRNA |
CTD |
PMID:18198484 |
|
NCBI chr10:103,798,290...103,816,923
Ensembl chr10:103,798,291...103,816,287
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
decreases expression |
EXP |
Paraquat results in decreased expression of GRK2 protein |
CTD |
PMID:24521700 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Grm2 |
glutamate metabotropic receptor 2 |
affects expression |
EXP |
Paraquat affects the expression of GRM2 mRNA |
CTD |
PMID:15206577 |
|
NCBI chr 8:115,344,999...115,358,628
Ensembl chr 8:115,344,999...115,358,046
|
|
G |
Grm6 |
glutamate metabotropic receptor 6 |
increases expression |
EXP |
Paraquat results in increased expression of GRM6 mRNA |
CTD |
PMID:18198484 |
|
NCBI chr10:36,345,503...36,363,416
Ensembl chr10:36,345,939...36,360,665
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
affects expression increases phosphorylation decreases expression multiple interactions |
EXP ISO |
Paraquat affects the expression of GSK3A mRNA Paraquat results in increased phosphorylation of GSK3A protein Paraquat results in decreased expression of GSK3A protein 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in decreased expression of GSK3A protein modified form] |
CTD |
PMID:15206577 PMID:28414160 PMID:30205152 |
|
NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases phosphorylation increases phosphorylation decreases expression |
ISO |
Lithium Chloride inhibits the reaction [Paraquat results in decreased phosphorylation of GSK3B protein]; Paraquat results in increased expression of and results in increased phosphorylation of GSK3B protein Paraquat results in increased phosphorylation of GSK3B protein 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat inhibits the reaction [TNFRSF10B protein binds to GSK3B protein]]; 6-bromoindirubin-3'-oxime promotes the reaction [Paraquat results in decreased expression of GSK3B protein modified form]; Paraquat inhibits the reaction [TNFRSF10B protein binds to GSK3B protein]; WNT1 protein inhibits the reaction [Paraquat results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:22292029 PMID:24634145 PMID:28414160 PMID:30171970 PMID:30205152 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases expression decreases activity affects expression multiple interactions increases expression |
ISO EXP |
Paraquat results in decreased expression of GSR mRNA; Paraquat results in decreased expression of GSR protein Paraquat results in decreased activity of GSR protein Paraquat affects the expression of GSR protein [Plant Extracts co-treated with Paraquat] results in increased expression of GSR mRNA; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in decreased activity of GSR protein]; Paraquat inhibits the reaction [naringenin results in increased expression of GSR mRNA] [Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Acetylcysteine co-treated with Paraquat] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat] results in increased activity of GSR protein; Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [Paraquat results in decreased activity of GSR protein]; Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]; Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein] Paraquat results in increased expression of GSR mRNA Dapsone inhibits the reaction [Paraquat results in decreased expression of GSR protein]; Dapsone inhibits the reaction [Paraquat results in increased expression of GSR mRNA] |
CTD |
PMID:10699569 PMID:12954614 PMID:15754033 PMID:16797015 PMID:17215068 PMID:20553223 PMID:21765237 PMID:23159886 PMID:24141985 PMID:24561720 PMID:25724285 PMID:28467894 PMID:30185695 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gss |
glutathione synthetase |
multiple interactions increases expression |
ISO |
SIRT6 promotes the reaction [Paraquat results in increased expression of GSS mRNA] |
CTD |
PMID:31216030 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP ISO |
Paraquat results in increased expression of GSTA2 mRNA; Paraquat results in increased expression of GSTA3 mRNA Paraquat results in increased expression of GSTA1 mRNA |
CTD |
PMID:16128001 PMID:16328009 PMID:20888808 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
decreases expression increases expression |
ISO |
Paraquat results in decreased expression of GSTA3 mRNA Paraquat results in increased expression of GSTA2 mRNA; Paraquat results in increased expression of GSTA3 mRNA |
CTD |
PMID:12595580 PMID:16128001 PMID:17215068 PMID:18620719 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions increases expression increases activity |
EXP |
[Acetylcysteine co-treated with EUK-134] promotes the reaction [[Zinc Sulfate co-treated with Paraquat] results in increased activity of GSTA4 protein]; [EUK-134 co-treated with Acetylcysteine] promotes the reaction [Paraquat results in increased activity of GSTA4 protein]; [Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; [Zinc Sulfate co-treated with Paraquat] results in increased activity of GSTA4 protein; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Paraquat results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Paraquat results in increased expression of GSTA4 mRNA]; Paraquat promotes the reaction [Zinc Sulfate results in increased expression of GSTA4 mRNA]; Paraquat results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Paraquat results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Paraquat results in increased expression of GSTA4 mRNA]; Zinc Sulfate promotes the reaction [Paraquat results in increased expression of GSTA4 mRNA] Paraquat results in increased expression of GSTA4 mRNA; Paraquat results in increased expression of GSTA4 protein |
CTD |
PMID:20553223 PMID:20888808 PMID:23159886 PMID:24521700 PMID:25724285 |
|
NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases expression |
ISO |
Paraquat results in increased expression of GSTA1 mRNA |
CTD |
PMID:16128001 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Paraquat results in increased expression of GSTM1 mRNA |
CTD |
PMID:16128001 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression decreases expression |
EXP ISO |
Paraquat results in increased expression of GSTM2 mRNA Paraquat results in decreased expression of GSTM2 mRNA |
CTD |
PMID:16128001 PMID:16555045 PMID:17935786 PMID:21371552 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstm3 |
glutathione S-transferase mu 3 |
increases expression |
ISO |
Paraquat results in increased expression of GSTM3 mRNA |
CTD |
PMID:20883675 |
|
NCBI chr 2:210,685,204...210,688,273
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression affects expression |
ISO |
Paraquat results in increased expression of GSTM3 mRNA Paraquat affects the expression of GSTM5 mRNA |
CTD |
PMID:16128001 PMID:20883675 PMID:27788593 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
increases expression |
ISO |
Paraquat results in increased expression of GSTO1 mRNA |
CTD |
PMID:16128001 |
|
NCBI chr 1:267,607,437...267,617,387
Ensembl chr 1:267,607,418...267,617,387
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression increases expression multiple interactions |
ISO |
Paraquat results in decreased expression of GSTP1 protein Paraquat results in increased expression of GSTP1 mRNA [Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Dapsone inhibits the reaction [Paraquat results in decreased expression of GSTP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA] |
CTD |
PMID:16128001 PMID:18620719 PMID:21765237 PMID:23963992 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects response to substance |
ISO |
GSTT1 protein affects the susceptibility to Paraquat |
CTD |
PMID:23045187 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
increases expression |
EXP |
Paraquat results in increased expression of GSTT2 protein |
CTD |
PMID:24521700 |
|
NCBI chr20:13,760,810...13,764,481
Ensembl chr20:13,760,810...13,764,475
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
increases expression multiple interactions |
ISO |
Paraquat results in increased expression of GSTZ1 mRNA [Paraquat co-treated with Quercetin] results in increased expression of GSTZ1 mRNA; Paraquat inhibits the reaction [naringenin results in increased expression of GSTZ1 mRNA] |
CTD |
PMID:22996356 PMID:24561720 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Gtpbp1 |
GTP binding protein 1 |
decreases expression |
ISO |
Paraquat results in decreased expression of GTPBP1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 7:120,923,274...120,947,723
Ensembl chr 7:120,923,274...120,947,723
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
increases expression |
EXP |
Paraquat results in increased expression of GUCY1A1 mRNA |
CTD |
PMID:20388547 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Guk1 |
guanylate kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:45,535,617...45,552,455
Ensembl chr10:45,535,627...45,543,897
|
|
G |
H2ac20 |
H2A clustered histone 20 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of H2AC20 mRNA [Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:198,360,271...198,360,735
Ensembl chr 2:198,360,301...198,360,678
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
ATG7 protein affects the reaction [Paraquat results in increased expression of H2AX protein] |
CTD |
PMID:28012437 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
H2bu1 |
H2B.U histone 1 |
decreases expression multiple interactions |
ISO |
Paraquat results in decreased expression of H2BC9 mRNA [Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:45,296,638...45,297,385
Ensembl chr10:45,296,638...45,297,385
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[ABCB1A gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of HAVCR1 mRNA; [ABCB1B gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of HAVCR1 mRNA; [SLC47A1 gene mutant form results in increased susceptibility to Paraquat] which results in increased expression of HAVCR1 mRNA |
CTD |
PMID:21991918 PMID:25015657 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:15,602,794...15,603,649
Ensembl chr10:15,602,794...15,603,649
|
|
G |
Hbb |
hemoglobin subunit beta |
decreases expression |
ISO |
Paraquat results in decreased expression of HBB-B1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hdac4 |
histone deacetylase 4 |
decreases expression |
EXP |
Paraquat results in decreased expression of HDAC4 protein |
CTD |
PMID:21777615 |
|
NCBI chr 9:99,052,945...99,299,715
Ensembl chr 9:99,057,089...99,299,715
|
|
G |
Hdac7 |
histone deacetylase 7 |
decreases expression |
EXP |
Paraquat results in decreased expression of HDAC7 protein |
CTD |
PMID:21777615 |
|
NCBI chr 7:139,280,396...139,319,108
Ensembl chr 7:139,281,187...139,318,455
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Paraquat results in increased expression of HERPUD1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:169,463,196...169,469,795
Ensembl chr 5:169,464,989...169,467,153
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
|
|
G |
Heyl |
hes-related family bHLH transcription factor with YRPW motif-like |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 5:140,923,914...140,940,905
Ensembl chr 5:140,923,914...140,940,905
|
|
G |
Hfe |
homeostatic iron regulator |
affects response to substance multiple interactions |
ISO |
HFE protein alternative form affects the susceptibility to Paraquat [HFE protein alternative form affects the susceptibility to Paraquat] which affects the expression of NFE2L2; HFE protein alternative form affects the reaction [Paraquat results in decreased expression of TOMM20 protein]; HFE protein alternative form affects the reaction [Paraquat results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [HFE protein alternative form affects the susceptibility to Paraquat] |
CTD |
PMID:32540480 |
|
NCBI chr17:43,661,276...43,669,327
Ensembl chr17:43,661,222...43,669,985
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
ISO |
Paraquat results in increased expression of HGF mRNA |
CTD |
PMID:16324872 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO EXP |
Paraquat results in increased expression of HIF1A protein Paraquat results in increased expression of HIF1A mRNA; Paraquat results in increased expression of HIF1A protein HIF1A protein affects the reaction [Paraquat results in decreased expression of TJP1 protein]; HIF1A protein affects the reaction [Paraquat results in increased expression of ACTA2 protein] |
CTD |
PMID:26781174 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hist3h2a |
histone cluster 3, H2a |
multiple interactions decreases expression |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2AC6 mRNA Paraquat results in decreased expression of H2AC6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:45,297,603...45,299,155
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
|
|
G |
Hm13 |
histocompatibility minor 13 |
decreases expression |
ISO |
Paraquat results in decreased expression of H13 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 3:148,150,695...148,189,623
Ensembl chr 3:148,150,698...148,189,623
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:65,159,944...65,275,408
Ensembl chr 7:65,159,944...65,275,408
|
|
G |
Hmgb1 |
high mobility group box 1 |
increases expression multiple interactions |
EXP |
Paraquat results in increased expression of HMGB1 mRNA Febuxostat inhibits the reaction [Paraquat results in increased expression of HMGB1 mRNA] |
CTD |
PMID:19497220 PMID:30726711 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmgcl |
3-hydroxy-3-methylglutaryl-CoA lyase |
decreases expression |
EXP ISO |
Paraquat results in decreased expression of HMGCL mRNA |
CTD |
PMID:17077588 PMID:21371552 |
|
NCBI chr 5:154,294,841...154,308,582
Ensembl chr 5:154,294,806...154,308,640
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:80,134,557...80,142,902
Ensembl chr X:80,134,557...80,142,902
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions affects expression affects activity increases activity decreases expression increases expression |
EXP ISO |
[Mifepristone co-treated with Paraquat] results in increased expression of HMOX1 mRNA; [Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of HMOX1 mRNA; alpha-Tocopherol inhibits the reaction [Paraquat results in increased activity of HMOX1 protein]; Curcumin inhibits the reaction [Paraquat results in increased activity of HMOX1 protein]; Estradiol affects the reaction [Paraquat affects the expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [[Mifepristone co-treated with Paraquat] results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Paraquat results in increased expression of HMOX1]; SB 203580 promotes the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of HMOX1 mRNA] Paraquat affects the expression of HMOX1 mRNA Paraquat affects the activity of HMOX1 protein Paraquat results in decreased expression of HMOX1 mRNA; Paraquat results in decreased expression of HMOX1 protein Paraquat results in increased expression of HMOX1 mRNA; Paraquat results in increased expression of HMOX1 protein Paraquat results in increased expression of HMOX1; Paraquat results in increased expression of HMOX1 mRNA; Paraquat results in increased expression of HMOX1 protein 2-tert-butylhydroquinone inhibits the reaction [Paraquat results in increased expression of HMOX1 protein]; [SIRT6 protein mutant form results in decreased activity of SIRT6 protein] inhibits the reaction [Paraquat promotes the reaction [SMARCA4 protein binds to HMOX1 enhancer]]; [SIRT6 protein mutant form results in decreased activity of SIRT6 protein] inhibits the reaction [Paraquat results in increased expression of HMOX1 mRNA]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Paraquat results in increased expression of HMOX1 protein]; Paraquat affects the reaction [APOD protein affects the expression of HMOX1 protein]; Paraquat promotes the reaction [POLR2A protein modified form binds to HMOX1 gene]; Paraquat promotes the reaction [SIRT6 protein binds to HMOX1 gene]; Paraquat promotes the reaction [SMARCA4 protein binds to HMOX1 enhancer]; Paraquat promotes the reaction [SMARCC2 protein binds to HMOX1 enhancer]; plant extract, Puerariae Radix inhibits the reaction [Paraquat results in decreased expression of HMOX1 protein]; resolvin D1 analog inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; resolvin D1 inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; Resveratrol promotes the reaction [Paraquat results in increased activity of HMOX1 protein]; SIRT1 protein affects the reaction [Paraquat affects the activity of HMOX1 protein]; SIRT6 promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; SIRT6 protein promotes the reaction [Paraquat promotes the reaction [POLR2A protein modified form binds to HMOX1 gene]]; SIRT6 protein promotes the reaction [Paraquat promotes the reaction [SMARCA4 protein binds to HMOX1 enhancer]]; SIRT6 protein promotes the reaction [Paraquat promotes the reaction [SMARCC2 protein binds to HMOX1 enhancer]]; SMARCC2 protein mutant form inhibits the reaction [Paraquat results in increased expression of HMOX1 mRNA]; SMARCC2 protein promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein; [Paraquat co-treated with naringenin] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Quercetin] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Thioctic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Thioctic Acid] results in increased expression of HMOX1 protein; [Quercetin co-treated with Paraquat] results in increased expression of HMOX1 protein; [SIRT6 protein results in decreased susceptibility to Paraquat] inhibits the reaction [NFE2L2 protein binds to HMOX1 enhancer]; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; NFE2L2 mRNA promotes the reaction [Paraquat promotes the reaction [SIRT6 protein binds to HMOX1 gene]]; Paraquat promotes the reaction [SIRT6 protein binds to HMOX1 gene]; Resveratrol promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [Paraquat results in increased expression of HMOX1 protein] Paraquat affects the expression of HMOX1 mRNA; Paraquat affects the expression of HMOX1 protein |
CTD |
PMID:11181820 PMID:12180188 PMID:15527874 PMID:15728566 PMID:16263688 PMID:16328009 PMID:16555045 PMID:16854511 PMID:17215068 PMID:17409708 PMID:17935786 PMID:18620719 PMID:19080378 PMID:20095327 PMID:20600150 PMID:21688324 PMID:21735318 PMID:22493042 PMID:22709784 PMID:22983789 PMID:22996356 PMID:23546295 PMID:23603004 PMID:23649336 PMID:24376630 PMID:24521700 PMID:24561720 PMID:24812154 PMID:25169090 PMID:26598004 PMID:26649146 PMID:26708779 PMID:26758514 PMID:26935021 PMID:27788593 PMID:28467894 PMID:29950142 PMID:30562684 PMID:30571954 PMID:31216030 PMID:31715309 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
increases expression |
EXP |
Paraquat results in increased expression of HMOX2 mRNA |
CTD |
PMID:17935786 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression decreases expression |
ISO |
Paraquat results in increased expression of HNRNPA2B1 mRNA alternative form Paraquat results in decreased expression of HNRNPA2B1 protein |
CTD |
PMID:17064354 PMID:27111068 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[HNRNPC protein binds to HNRNPC protein alternative form] which results in decreased susceptibility to Paraquat |
CTD |
PMID:16960656 |
|
NCBI chr15:28,486,605...28,517,353
Ensembl chr15:28,486,617...28,517,353
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
increases expression |
ISO |
Paraquat results in increased expression of HNRNPD mRNA alternative form |
CTD |
PMID:17064354 |
|
NCBI chr14:11,256,163...11,274,684
Ensembl chr14:11,256,268...11,274,578
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
decreases expression |
ISO |
Paraquat results in decreased expression of HNRNPH1 mRNA; Paraquat results in decreased expression of HNRNPH1 protein |
CTD |
PMID:27111068 |
|
NCBI chr10:35,872,619...35,879,911
Ensembl chr10:35,870,232...35,879,910
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions increases expression |
ISO EXP |
[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA Paraquat results in increased expression of HNRNPK mRNA |
CTD |
PMID:16328009 PMID:18386188 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Homer2 |
homer scaffold protein 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of HOMER2 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 1:143,443,300...143,535,579
Ensembl chr 1:143,443,300...143,535,583
|
|
G |
Hoxa3 |
homeobox A3 |
decreases expression |
ISO |
Paraquat results in decreased expression of HOXA3 mRNA |
CTD |
PMID:26824344 |
|
NCBI chr 4:82,137,802...82,181,836
Ensembl chr 4:82,138,683...82,141,385
|
|
G |
Hoxb13 |
homeo box B13 |
increases response to substance |
ISO |
HOXB13 protein results in increased susceptibility to Paraquat |
CTD |
PMID:24213000 |
|
NCBI chr10:84,031,955...84,034,228
Ensembl chr10:84,031,955...84,034,228
|
|
G |
Hpcal1 |
hippocalcin-like 1 |
increases expression |
ISO |
Paraquat results in increased expression of HPCAL1 mRNA |
CTD |
PMID:12595580 |
|
NCBI chr 6:43,001,920...43,109,083
Ensembl chr 6:43,001,948...43,109,071
|
|
G |
Hpn |
hepsin |
decreases expression |
ISO |
Paraquat results in decreased expression of HPN mRNA |
CTD |
PMID:16797015 |
|
NCBI chr 1:89,534,112...89,549,575
Ensembl chr 1:89,534,106...89,543,967
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases expression |
ISO |
Paraquat results in increased expression of HPRT1 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr X:158,196,640...158,228,815
Ensembl chr X:158,197,149...158,228,749
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
affects splicing |
ISO |
Paraquat affects the splicing of HRAS mRNA |
CTD |
PMID:23613995 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
decreases expression |
ISO |
Paraquat results in decreased expression of HRK mRNA |
CTD |
PMID:18836921 |
|
NCBI chr12:44,008,879...44,029,211
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression decreases expression |
EXP |
Paraquat results in increased expression of HSD11B1 mRNA Paraquat results in decreased expression of HSD11B1 mRNA; Paraquat results in decreased expression of HSD11B1 protein |
CTD |
PMID:18198484 PMID:31128353 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
decreases expression increases expression |
ISO |
Paraquat results in decreased expression of HSD17B12 mRNA Paraquat results in increased expression of HSD17B12 mRNA |
CTD |
PMID:21371552 |
|
NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
decreases expression |
EXP |
Paraquat results in decreased expression of HSD17B3 mRNA; Paraquat results in decreased expression of HSD17B3 protein |
CTD |
PMID:31128353 PMID:31610511 |
|
NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Paraquat results in increased expression of HSD3B1 mRNA; Paraquat results in increased expression of HSD3B1 protein |
CTD |
PMID:31128353 |
|
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions increases expression |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; SIRT6 promotes the reaction [Paraquat results in increased expression of HSF1 mRNA]; SMARCC2 protein promotes the reaction [Paraquat results in increased expression of HSF1 mRNA] |
CTD |
PMID:23963992 PMID:31216030 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA] |
CTD |
PMID:18386188 PMID:23963992 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
increases expression |
EXP |
Paraquat results in increased expression of HSP90B1 mRNA |
CTD |
PMID:17935786 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
Paraquat results in decreased expression of HSPA1A mRNA |
CTD |
PMID:20883675 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
decreases response to substance |
ISO |
HSPA1L protein results in decreased susceptibility to Paraquat |
CTD |
PMID:24887138 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
decreases expression |
ISO |
Paraquat results in decreased expression of HSPA2 mRNA |
CTD |
PMID:20883675 |
|
NCBI chr 6:99,433,575...99,436,288
Ensembl chr 6:99,433,550...99,436,289
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO EXP |
Paraquat results in increased expression of HSPA5 mRNA; Paraquat results in increased expression of HSPA5 protein [Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA Minocycline inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of HSPA5 mRNA]; NFE2L2 mutant form inhibits the reaction [Paraquat results in increased expression of HSPA5 protein] EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]; salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein] |
CTD |
PMID:17935786 PMID:18198484 PMID:18386188 PMID:19735704 PMID:20883675 PMID:22245251 PMID:22678742 PMID:24912635 PMID:27442881 PMID:28986289 PMID:30185695 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
increases expression |
EXP |
Paraquat results in increased expression of HSPA9 mRNA |
CTD |
PMID:17935786 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
affects expression decreases expression |
EXP ISO |
Paraquat affects the expression of HSPB1 mRNA Paraquat results in decreased expression of HSPB1 mRNA |
CTD |
PMID:15206577 PMID:20883675 PMID:21371552 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression multiple interactions decreases expression |
EXP ISO |
Paraquat results in increased expression of HSPD1 protein HSPD1 protein promotes the reaction [Paraquat results in increased expression of IL1B mRNA]; HSPD1 protein promotes the reaction [Paraquat results in increased expression of IL6 mRNA]; HSPD1 protein promotes the reaction [Paraquat results in increased expression of MYD88 protein]; HSPD1 protein promotes the reaction [Paraquat results in increased expression of NOS2 mRNA]; HSPD1 protein promotes the reaction [Paraquat results in increased expression of TLR4 protein]; HSPD1 protein promotes the reaction [Paraquat results in increased expression of TNF mRNA] Paraquat results in decreased expression of HSPD1 protein Paraquat results in increased expression of HSPD1 mRNA |
CTD |
PMID:11746186 PMID:20883675 PMID:27788593 PMID:29441825 PMID:30584891 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP ISO |
Paraquat results in increased expression of HSPE1 mRNA |
CTD |
PMID:17935786 PMID:20883675 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
decreases expression |
EXP |
Paraquat results in decreased expression of HTR1B mRNA |
CTD |
PMID:18198484 |
|
NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
|
![JBrowse link JBrowse link]() |